Sygnity FY2025 consolidated financial statements ↗
SSF_Sygnity_2025-12-31_pl_EN.pdf: printed pp.4-8 statements; pp.31-33 revenues/tax; pp.41-42 acquisitions; p.46 JV. PDF pages are printed pages +1.
Published Mar 24, 2026 · Reviewed Oct 27, 20268 of 11 research checks complete. Still to complete: Security and evidence base; Opportunities and funded scenarios; Variant view and catalysts · September 2026 reported earning-power bridge, cash and claims; October g.on pro forma
Maintain and develop critical software for regulated customers, then deploy surplus owner cash into independent software businesses. Project execution, employee economics and actual deal returns determine compounding.
Software owner cash and disciplined acquisitions · September 2026 reported earning-power bridge, cash and claims; October g.on pro forma
| Driver | Downside | Base | Upside |
|---|---|---|---|
| Common cash payout | 0.0% | 0.0% | 0.0% |
| Exit / after-financing owner cash | 11.41× | 15.71× | 15.71× |
| Net dilution beyond charged compensation | 0.0% | 0.0% | 0.0% |
| Available cash deployment fraction | 100.0% | 13.6% | 27.3% |
| Organic revenue growth | Year 1: -2.0% Years 2–5: 0.0% | Year 1: 9.5% Years 2–3: 7.0% Years 4–5: 5.5% | Year 1: 13.0% Years 2–3: 11.0% Years 4–5: 9.0% |
| Owner-cash margin on organic revenue | Year 1: 24.8% Years 2–5: 23.3% | Years 1–5: 24.8% | Years 1–2: 24.8% Years 3–5: 25.3% |
| Price paid per unit of acquired revenue | Years 1–5: 1.06× | Years 1–5: 1.06× | Years 1–5: 1.06× |
| Owner-cash margin of acquired businesses | Years 1–5: 16.2% | Years 1–5: 16.2% | Years 1–5: 16.2% |
| Acquired revenue growth after purchase | Years 1–5: 0.0% | Years 1–2: 0.0% Years 3–5: 3.4% | Years 1–2: 0.0% Years 3–5: 3.4% |
| Deal budget (capital available for acquisitions) | Years 1–3: 0.00 Years 4–5: 14.02 | Year 1: 26.29 Year 2: 27.19 Year 3: 28.11 Year 4: 29.07 Year 5: 30.06 | Year 1: 35.74 Years 2–3: 44.20 Years 4–5: 58.40 |
Researched 27 October 2026; economic engine, unit economics and history rebuilt from five years of filings on 3 November 2026. Money is PLN millions unless stated. Source IDs refer to sources/registry.json, fact IDs to financials/facts.json, and named calculations to valuation/calculations.json.
Sygnity builds, implements and services software for the Polish state, the central bank, banks, utilities and, since 2024, a few acquired product niches. Accounting, payment, welfare, labour-market and billing workflows run on systems Sygnity wrote, which gives a reason to keep paying the incumbent. Regulation and changes in customer processes create development work. Switching means migration, retraining, testing and operational risk; it remains possible, and public tenders can be lost.
The fiscal year moved from October–September to the calendar year: FY2020/21 and FY2021/22 end in September, FY2022/23 ran 15 months to December 2023, and 2024 onward are calendar years. Calendar 2021 and 2022 below are derived from the audited fiscal years and the Q1 interim reports; calendar 2023 is the audited comparative column (revenueCY2021–revenueCY2023 and the matching cash facts).
Sygnity's value comes from owning the code and domain knowledge of systems that a ministry, the central bank or a distribution utility cannot easily replace. The incumbent then gets most of the multi-year maintenance and change-request work on those systems: 48-month renewals across six Ministry of Family systems in 2024 (pracaGovContractMax and the PWI, AC and ZC contracts, sgn-fy24-report pp.32-33), and two annexes taking the NBP accounting-system contract to PLN135m gross for 2024–2027, the second "due to an increase in the Employer's needs" (sgn-nbp-contract). The work is paid largely in advance or on delivery and needs almost no capital, so owner cash is close to after-tax operating profit.
Since TSS Europe (Topicus, in the Constellation family) took control in 2022, two more steps were added: reprice and prune the franchise, then send the surplus cash into small vertical-software companies. Most of the value so far came from the repricing step, not from acquisitions. Between calendar 2021 and 2025, NOPAT rose by 44.8 (nopatChangeWindow). Deals explain about 8.5–13.6 of that: the 2024 deals' annualized profit or cash proxy of 6.7–11.8 (deals2024AnnualProfit, deals2024CashProxy), plus DocLogix and one month of Mednow. The remaining 31–36 came from the existing business, while working capital released 24.8 of cash (workingCapitalReleasedWindow). The repricing was a one-time step that is now largely complete. The forward mechanism has to be margin retention against wage inflation, plus deployment of cash that otherwise sits idle.
Comparable firms are chosen by these traits, not by the industry label.
Growth vehicle: Mixed: organic and acquisitions. Revenue rose from 205.9 in 2021 to 350.3 in 2025. Companies bought in 2024–2025 contributed roughly 51 of 2025 revenue (Edrana, Sagra, DocLogix, Mednow at their run rates), so the organic base grew by about 80 over the period, with negative net capital. Deals began only in 2024 under the current owner and were 8.0% of revenue over 2023–2025. The model grows the organic base and adds deals at measured entry yields, on a record of only two active deal years.
Capital intensity: 0.6% of sales, asset-light. Capital spending is about 0.6% of revenue: computers and offices for software engineers. Tangible capital is negative (−24.3 in 2025) because customers prepay and staff costs are billed promptly. Growth needs people and, since 2024, acquisition cash (8.0% of revenue over 2023–2025).
Comparables. A comparable firm writes and maintains mission-critical software for government, central-bank, banking and utility customers, earns from long implementation and maintenance relationships, needs almost no fixed capital, and has recently started bolt-on acquisitions. Its revenue depends on the timing of public procurement. Not the label: "IT services" suggests consulting priced by the hour; Sygnity owns the systems its customers run and earns product-like maintenance margins.
Declared in valuation/model.json (businessProfile). npm run check measures deal and capital intensity from the reported facts, and the outside view grades the forecast only against firms that share them.
Calendar 2025 (audited) unless stated; calculations named in brackets.
| Measure | Value | Definition |
|---|---|---|
Revenue (revenue2025) | 350.3 | +19.5% on 2024; about 14% excluding businesses bought in 2025 (sgn-presentation) |
| Gross margin | 46.5% (FY to Sep 2022: 28.5%) | gross profit / revenue (grossMargin2025, grossMarginFY2022) |
| EBIT margin | 25.5% (FY2022: 12.0%) | statutory operating profit (ebitMargin2025) |
| EBIT before acquisition amortization | 96.7 (27.6%) | plus 7.2 amortization of acquired intangibles (ebitBeforePpa2025) |
| Incremental EBIT margin | 39.7% (2024→2025) | ΔEBIT 22.7 / Δrevenue 57.1 (incrementalMargin2025) |
| Trailing June 2026 EBIT | 106.0 (26.2% of 405.3) | FY2025 + H1 2026 − H1 2025 (sgn-h126 p.9) |
| Operating working capital | −38.5 | receivables 44.7 + contract assets 17.8 + contract costs/inventory 1.3 − trade and other liabilities 61.0 − contract liabilities 41.3 (operatingWorkingCapital2025) |
| Receivable / contract-liability days | 65 / 43 | (receivables + contract assets) / revenue; customer prepayments / revenue |
| PP&E / right-of-use assets | 5.5 / 8.6 | |
| Tangible capital including leases | −24.3 | working capital + PP&E + ROU (tangibleCapital2025) |
| Return on tangible capital (leases capitalized) and ROCE (leases expensed) | not meaningful | capital is negative under both definitions: customers and employees fund the business |
| Return on capital including goodwill and acquired intangibles | 34.1% after tax (36.8% before acquisition amortization) | NOPAT 72.5 at 19% / 212.6 (returnOnCapitalIncGoodwill2025) |
| Same, excluding goodwill from mergers before 2024 | 131% | 72.5 / 55.5 (recentCapital2025); 157.2 of goodwill dates from the EMAX and Polsoft era |
| Debt / leases / cash | 0 bank debt (last 12.0 loan repaid in 2025), bond 0.1 / leases 9.2 / cash 187.7 (225.1 at June 2026) | sgn-fy25 p.6, sgn-h126 |
| Revenue / EBIT per average FTE | 0.407 / 0.104 (FY2022: 0.309 / 0.037) | 860 FTE in 2025, 752 of them in implementation (revenuePerFte2025) |
Normalization before returns: capex (1.8) was below own-asset D&A (2.6 = 13.96 total − 4.10 right-of-use − 7.24 acquisition amortization), so maintenance spending is not understated in a way that matters at this scale. There are no minorities. Mednow is in the 2025 accounts for one month only, and the model adds its missing months separately. Cash tax is the main normalization: 2025 tax paid was 8.6 against 18.2 of current tax, because loss carry-forwards ran out (no tax losses remained at June 2026, sgn-h126 note 12.3; H1 2026 paid 24.3). The model charges current tax. The effective rate of 14.9% reflects the IP-box regime, so returns at the 19% statutory rate are slightly conservative.
Sygnity reports one IT segment (sgn-fy25 note 7). Its management report gives revenue by customer sector, and the revenue note splits servicing from implementation. Neither split is a profit split. Re-cut by how value is created:
| Economic unit | Revenue evidence | Profit evidence | Demand driver | Character |
|---|---|---|---|---|
| Public-administration franchise (Ministry of Family welfare and labour systems, Poczta Polska ZST, police CSD) | 96.9 in 2024 (33%); FY2022 87.7 on 98 projects (sectorPublic2024, sectorPublicFY2022) | not disclosed | statutory programme changes, EU-funded digitization, 48-month maintenance renewals | recurring core, with tender risk on new builds |
| Central-bank and financial-market franchise (NBP ZSK accounting, brokerage and depository systems, bank reporting) | 84.8 in 2024 (29%); FY2022 69.8 | not disclosed | regulation (NBP, KNF, KDPW), bank IT budgets | recurring; NBP alone is up to about 27/yr net under its 2024–2027 contract |
| Utilities billing and metering (PGE multiZBYT, SUD, AMS) | 64.5 in 2024 (22%); FY2022 48.0 | not disclosed | energy-market regulation: Solidarity Shield price caps (2023 act), CSIRE data hub, balancing rules | recurring base plus regulation-driven waves; part of the growth is cyclical |
| Acquired product companies (Sagra retail SaaS, Edrana ERP Baltics, DocLogix, Mednow hospital IT, g.on Germany) | retail 20.0 in 2024 (Sagra about 90%); about 51 of 2025 revenue (estimate from the 2024 run rates plus the 2025 contributions) | roughly 15 of about 111 portfolio owner cash, about 13%: Edrana 2.3 and Sagra 4.3 annualized net profit, DocLogix about 0.8, plus model proxies of 0.5 for Mednow's missing months and 4.7 for g.on | customer vertical demand; SaaS and maintenance | small, growing by purchase |
Across revenue streams, 2025 servicing was 144.2 (41%, +27% on 2024), implementation 189.0 (54%, +13%) and licences 15.8 (4.5%) (sgn-fy25 note 9). "Implementation" includes change requests on Sygnity's own installed systems, which behave like recurring development rather than one-off projects. The NBP annex is development work added to a maintenance contract.
Conclusions. Revenue share by sector says nothing about profit share, and the issuer does not disclose sector margins, so we do not allocate profit among the three franchises. About 87% of owner cash still comes from the incumbent franchises and about 13% from acquired businesses. Utilities grew fastest from FY2022 to 2024 (48.0 to 64.5, +34%) during the Solidarity Shield and CSIRE adaptation wave. Up to about 16 of revenue, perhaps 6–7 of EBIT at the group's incremental margin, may be regulation-timed rather than permanent.
The unit through which Sygnity adds value is the installed-system relationship, and the intervention that mattered is TSS's ownership since 2022. The before-and-after comparison is therefore the whole incumbent business per delivery employee, FY to September 2022 (the last year before TSS's influence) against calendar 2025. Contracts are not costed separately in public filings.
| Per average FTE (PLN thousand) | FY2022 (685 FTE) | 2025 (860 FTE) | Change |
|---|---|---|---|
| Revenue | 309 | 407 | +32% |
| Subcontractors and other third-party services | 94 (30.4% of revenue) | 88 (21.6%) | lower in money as well as share |
| Payroll and benefits | 159 (51.5%) | 191 (46.9%) | +20%; average pay at the parent rose from 123 (FY2021) to 168 |
| D&A | 16 | 16 | 2025 includes acquired-intangible amortization |
| Gross profit | 88 | 189 | ×2.1 |
| EBIT | 37 | 104 | ×2.8 |
| Tangible capital | negative | negative | prepayments and payables exceed receivables |
The levers were pruning and price, not buying power. Projects fell from 538 (FY2021) to 397 over the 15 months to December 2023 (projectsFY2021, projectsFY2023), while revenue per public-sector project rose from 0.89 (FY2022) to 1.17 (2024). The share of subcontracted work fell by about 9 points of revenue. Revenue per head rose faster than pay. mBank's October 2024 note records management's aim of winding down projects with insufficient profit (sgn-mbank-2024).
A representative maintenance unit: the Praca.gov.pl contract (November 2024) has a 48-month maximum of 14.2 gross, about 11.5 net of VAT, or 2.9 a year. At the 2025 group revenue per implementation FTE of 0.466, that is roughly six people. At the group's 2025 cost structure it would earn about 0.7–0.8 of EBIT a year on no tangible capital. This is an illustration from group averages, not a disclosed contract margin. The large unit is NBP: up to 135 gross (about 110 net) over 2024–2027, roughly 27 a year, or 7–8% of 2025 revenue.
Acquired companies are the second unit (edranaNetPrice … sagraAnnualProfit):
| Edrana Baltic (Feb 2024) | Sagra Technology (Mar 2024) | |
|---|---|---|
| Price net of acquired cash | 9.4 | 37.6 |
| Revenue, annualized from 11 / 10 months | 14.9 | 26.3 |
| Net profit, annualized | 2.3 (16%) | 4.3 (16%) |
| Price / net profit | 4.0x | 8.7x |
| Purchase-price intangibles | 11.3 | 40.7 |
| Tangible capital acquired | receivables 1.7, no material PP&E | receivables 2.2, PP&E 0.6 |
The two together cost 4.0x–7.1x a cash proxy, depending on whether the reported contributions bear purchase-price amortization (deals2024LowerMultiple, deals2024UpperMultiple). Their returns are entry yields, not post-integration results.
Failure case: e-Taxes. Sygnity won the Ministry of Finance e-Taxes system in 2013 on a fixed-price tender and subcontracted much of it to Fast Enterprises. The resulting court disputes ran for years, through the period of the 2018 creditor restructuring, and in February 2021 Sygnity settled by paying USD3.75m (about PLN14m) into deposit (fastEnterprisesSettlement, sgn-fy21-report p.24). The levers failed because, on a new-build tender where price decides, Sygnity carried subcontractor and scope risk without incumbency. The same exposure remains wherever Sygnity bids for greenfield public systems (sgn-fy24-report p.55).
Parent against subsidiaries, H1 2026 (added 3 November). The parent company is the organic franchise. In H1 2026 it earned a core operating margin (gross profit less selling and G&A) of 32.6% on 135.9 of revenue, up from 26.1%. The subsidiaries (SBS, Edrana, Sagra, DocLogix, Mednow), together with consolidation entries, earned about 9.9 of pretax on about 77.6 of revenue, roughly 13%, after acquisition amortization. The acquired units therefore run at well under half the parent's margin. Mednow's KPO hospital projects added revenue faster than profit: subsidiary over-time revenue rose +35.8 against a pretax gain of +3.9 (02-history.md). The repricing mechanism described above is a parent-company phenomenon. It has not been shown in the acquired companies, whose results are not reported separately.
ownerCashCY2025), was 104.4 in 2025 against NOPAT of 72.5 at 19%. The gap is explained by 14.1 of working-capital release, cash tax 9.6 below current tax, and non-cash acquisition amortization of 7.2. The normalized June-trailing bridge removes the first two and gives 94.6 (normalizedTrailingOwnerCash). The unit view, high margin on negative capital, matches the group cash record: 2021–2025 growth released net capital (totalCapitalDeployedWindow is only 64.9 including 70.1 of deals).mbankEbit2025Forecast). Actual 2025 EBIT was 89.5 and net profit 77.3. The consensus treated Sygnity as a tender-driven integrator with a stable margin. The repricing seen in the per-FTE table is what it missed.Where the consensus may still disagree: the market may treat 2025–2026 margins as the new normal. We treat them as the result of a one-time repricing whose durability depends on renewals and wage inflation. The H2 2026 and H1 2027 EBIT margins will settle it (prospective checks).
No fieldwork was done: no customer, employee or competitor interviews. Statements by management are evidence of what management says.
Sources: sgn-fy21, sgn-fy21-report, sgn-fy22, sgn-fy22-report, sgn-fy23, sgn-fy23-report, sgn-fy24, sgn-fy24-report, sgn-fy25, sgn-h126, sgn-q121, sgn-q122, sgn-presentation, sgn-nbp-contract, sgn-mbank-2024, asseco-pe-aggregator, sgn-asseco-h126.
Sygnity's history includes the ComputerLand/EMAX combination, the e-Taxes dispute and a 2018 creditor restructuring that was only completed in June 2021 (sgn-fy22 p.8 note). Its current economics should not be inferred only from the recovery off that distressed base. TSS Europe bought 72.68% in a 2022 tender at PLN12 a share (tssCallPrice, sgn-tss-call), which made Sygnity an acquisition platform inside the Topicus/Constellation family. Group affiliation brings experience and deal flow. It does not guarantee returns to minority shareholders.
Acquisitions since then: Edrana Baltic (February 2024), Sagra (March 2024), DocLogix (July 2025), Mednow, formerly Comarch HIS (December 2025), and g.on (October 2026, from TSS). Closing dates matter. DocLogix is fully in the trailing June 2026 window, Mednow for seven months, g.on not at all. A newly bought company's full-year earnings cannot simply be added on top of its already consolidated contribution.
The model uses calendar windows: FY2025 + H1 2026 − H1 2025, provisionally rolled to September with the 2 November preliminary release. The 2025 presentation's revenue bridge suggests about 14% growth excluding businesses bought in 2025. Some chart sub-bars do not add to their headline, so the numerical ledger uses statutory tables. The latest full statements are for H1 2026; the Q3 report is due 10 November 2026, and no Q3 actuals are invented.
Who decides and who pays:
| Customer | End user | Payer | Decision-maker |
|---|---|---|---|
| Ministries and agencies (welfare, labour market, foreigners' permits) | civil servants, labour offices, citizens | state budget, often EU or KPO co-financing | the ministry's IT department and procurement under public-procurement law |
| NBP (central bank) | accounting and back-office staff | NBP | NBP IT; renewals and annexes rather than open retenders |
| Distribution and sales utilities (PGE group) | billing and metering staff | the utility, which passes costs into regulated tariffs | utility IT, under deadlines set by the regulator (URE, PSE) |
| Banks, brokers and depositories | operations staff | bank IT budget | bank IT and compliance, driven by KNF, KDPW and exchange rules |
| Acquired niches (retailers, Baltic ERP users, hospitals, airports) | the business user | the customer | the owner or CIO |
Demand splits into four parts:
Measured cycle (calendar revenue, revenueCY2020–revenue2025): 218.7, 205.9, 219.1, 229.3, 293.2, 350.3. Revenue fell 6% in 2021, while projects were being pruned and the e-Taxes settlement closed. Servicing went from 75.0 (FY2021) and 75.6 (FY2022) to 70.6 a year over the 15-month FY2023, then to 113.8 in 2024 and 144.2 in 2025. H1 2026 servicing was 96.6 against 66.6 a year earlier, partly from acquisitions. The franchise has not shown a cyclical collapse. A test of public IT budgets through a recession is unavailable, because the 2020 shock coincided with Sygnity's own restructuring. We did not obtain a series of Polish public IT spending or EU-fund disbursement, which is the series that would measure the public-sector cycle.
Market misperception and the series that tests it. In 2023–2024 the sell-side saw a tender-driven integrator with a stable mid-teens margin: mBank forecast 17.6% EBIT for 2025 (sgn-mbank-2024). The actual margin was 25.5%. The belief was refuted by the reported EBIT margin and the rising servicing share, which are published every half-year. The present risk is the opposite misreading: treating regulation-timed utility work and the post-repricing margin as permanent.
Sygnity reports one segment. The parent company's separate statements (Sygnity S.A., which holds none of the acquired businesses) isolate the organic core, and IFRS 15 timing separates long projects from the rest. PLN m:
| H1 2024 | H1 2025 | H1 2026 | H1 2026 vs H1 2025 | |
|---|---|---|---|---|
| Group revenue | 131.4 | 158.4 | 213.5 | +55.0 (+34.7%) |
| Parent products and services (organic) | 99.6 | 116.1 | 135.5 | +19.5 (+16.8%) |
| of which parent maintenance | 35.7 | 41.4 | 51.1 | +9.7 (+23%) |
| of which parent implementation | 60.7 | 70.5 | 81.2 | +10.7 (+15%) |
| Subsidiaries and eliminations (group less parent) | about 32 | 41.8 | 77.6 | +35.8 |
| Group revenue recognized over time | 15.5 | 20.5 | 67.1 | +46.5 |
| of which subsidiaries | — | 6.3 | 42.1 | +35.8 |
| Group revenue at a point in time | 115.9 | 137.9 | 146.4 | +8.5 |
| of which subsidiaries | — | 35.5 | 35.5 | 0.0 |
| Licences / hardware | 4.7 / — | 6.7 / 0.5 | 10.8 / 1.3 | subsidiaries' licences +4.9 |
Sources: sgn-h126 pp.17, 44-45; sgn-h125 p.16; facts parentRevenueH12024 … pointInTimeH12026.
Quarterly over-time revenue was 11.3, 9.2, 13.9, 21.7 (2025), then 17.5 and 49.5 (Q1 and Q2 2026). Servicing was 30.8, 35.8, 36.0, 41.6, then 47.8 and 48.8.
What drives it:
subsidiaryPbtIncreaseH1).kpoWaveOwnerCash), with a range of about 3–8. The wave ends after August 2026.Verdict: the 2025–2026 level is mostly new and durable at the parent (statutory maintenance and development, +17–23% maintenance growth), plus a temporary KPO hospital wave inside the acquired Mednow that ends in Q3 2026. The model removes the wave from starting earnings and raises base growth to the through-cycle organic rate (07-assumption-register.md).
Competition happens in two places. At tender, for a new system, Sygnity faces the leading Polish integrators (Asseco Poland above all), international IT firms and consultancies, and price is often decisive (sgn-fy24-report p.55; sgn-mbank-2024). On an installed system, competition is weak. The incumbent owns the code, the domain staff and the operational history, so renewals and change requests usually come to Sygnity by annex or extension. Examples are the NBP annexes, six 48-month Ministry of Family contracts in 2024 and Poczta Polska's two-year maintenance renewal (23.6 gross).
Advantage in one sentence: Sygnity owns the knowledge and code of systems that the state, the central bank and utilities cannot switch without risking service continuity, so it captures the maintenance and regulatory change work on them. Evidence that this is durable is limited to contract continuity in the filings. We found no lost renewal of a major system in 2021–2026, but the filings would not necessarily disclose one, and we did no customer interviews.
Competitor count: the issuer expects consolidation among the largest players and more foreign entrants (sgn-fy24-report p.55). Topicus, which controls Sygnity, also owns about 24.8% of Asseco Poland: 9.99% bought from Cyfrowy Polsat, plus 14.84% of treasury shares at PLN85 closed on 1 October 2025 under a shareholders' agreement with Adam Góral (topicus-asseco). Sygnity's controller is therefore a large holder in its main competitor. That may soften head-to-head price competition, but it also gives TSS a choice of vehicle for Polish deals and talent. Comarch, which began a strategic-options review in January 2025, sold its hospital-software unit (Comarch HIS) to Sygnity in December 2025 (itwiz-comarch-his), so one competitor exited one niche. Share of the Polish IT market is not measured here.
The competitor that could hurt Sygnity is Asseco Poland. It has the scale and public-sector references to underbid when a ministry or NBP retenders a core system or replaces it in an EU-funded modernization. It hasn't done so visibly, because the customer bears the migration risk, and because the state's in-house IT centres, not rival vendors, are the more likely route to replacing outsourced maintenance. That second path is a hypothesis we have not tested.
| Counterparty | What they want | What Sygnity gives them | Their outside options | What would change the arrangement |
|---|---|---|---|---|
| TSS Europe / Topicus / Constellation (72.68% owner) | high-return deployment of cash into vertical software, long holding periods | a listed CEE platform with surplus cash, local M&A capacity and a profitable franchise | buy out minorities (the 2022 call reserved a future delisting "if an opportunity arises"); route CEE deals to other TSS units; sell group assets to Sygnity | a cheap price relative to value (buyout), or TSS needing a home for assets it owns |
| Ministries and agencies | uninterrupted statutory services at a defensible price | continuity, domain staff, fast regulatory changes | retender (public-procurement law), insource to state IT centres, replace in EU-funded programmes | price rises that attract audit scrutiny, a failed delivery, a political push for state-owned IT |
| NBP | reliable accounting and back-office systems | long-standing system knowledge | retender at the end of 2027 | delivery failure or a platform change |
| Utilities | compliance with regulatory deadlines | billing and metering systems already adapted | other billing vendors, group IT | consolidation of utility IT platforms |
| Employees (the scarce input) | pay, stability, career | pay up 37% per FTE 2021→2025 at the parent; incentive plan for up to 149 managers | other IT employers | wage inflation above price increases |
Dependence runs both ways. A ministry depends on Sygnity for systems it cannot easily rebuild. Sygnity depends on renewals that can be contested by tender. TSS gives discipline and deal flow but can also extract value: g.on came from TSS for EUR7.2m, about 1.5% of market value, with no stand-alone financials disclosed. TSS had flagged it four times since 2022 (current reports 40/2022, 25/2023, 9/2024, 15/2024; sgn-gon). Headlines about a counterparty's action show what it did, not why. We have no evidence of TSS's motive in the g.on sale beyond the stated strategy.
Sources: sgn-tss-call, sgn-fy21-report, sgn-fy22, sgn-fy22-report, sgn-fy23-report, sgn-fy24-report, sgn-fy25, sgn-h126, sgn-nbp-contract, sgn-gon, sgn-mbank-2024, sgn-presentation, sgn-calendar.
Two layers decide where Sygnity's cash goes. The six-person management board runs operations and proposes deals. TSS Europe (Topicus, in the Constellation family) owns 72.68%, appoints the supervisory-board majority and sets the capital-allocation frame. The model uses all 22,759,947 issued shares (unchanged since 2019) and charges award cost once. Money in PLN.
| Holder | Shares (3 Sep 2026) | Value at PLN94 | 2025 pay | How acquired | Background |
|---|---|---|---|---|---|
| TSS Europe B.V. | 16,542,399 (72.68%) | 1,555m | — | 2022 tender at PLN12 (about PLN199m) | Topicus/Constellation vertical-software acquirer |
| Barca Global Master Fund | 2,050,679 (9.01%) | 193m | — | market | fund |
| Maciej Różycki, CEO since May 2022 | 40,538 | 3.8m | 2.33m (base 0.90, bonus 1.39) | incentive transfers (25,663 at May 2026) | TSS investment and acquisition background |
| Mariusz Jurak, vice-chair, board since before 2021 | 31,486 | 3.0m | 1.28m | incentive transfers | long-standing Sygnity executive |
| Adam Larysz, board from 2025 | 20,552 | 1.9m | 1.79m | incentive transfers | board member responsible for a business sector |
| Daniel Fryga, vice-chair from 2025 | 12,599 | 1.2m | 1.95m | incentive transfers | not reviewed |
| Dorota Beksińska, board from 2025 | 10,485 | 1.0m | 1.20m | incentive transfers | board member responsible for a business sector |
| Monika Zientarska, CFO since Sep 2023 | 6,959 | 0.7m | 0.94m | incentive transfers | finance |
| Supervisory board: three TSS-linked members (unpaid), two independents (paid 0.14m each) | — | — | — | — | Eggink (audit chair) has decades of WSE board service |
Sources: sgn-h126 p.27; sgn-rem25 pp.6-11; sgn-fy24-report (management and supervisory-board biographies). No open-market purchases or sales by board members were found in 2025–2026. Holdings rose only through incentive transfers, including 56,266 shares in May 2026.
Whose interests dominate. Executives' wealth is mostly pay. If the stock compounded at 10% a year for five years, the CEO's 40,538 shares would gain about PLN2.3m, about one year of his 2025 pay. TSS's interest is almost entirely share value: a 10% move in the price changes its stake by about PLN156m. The management board as a whole cost PLN9.49m in 2025 (boardPay2025). That is 12% of 2025 net profit and 2.7% of revenue, a heavy charge for a company with 860 employees.
Compensation metrics (sgn-rem25 p.14): consolidated net profit, EBIT, ROIC and revenue growth, plus four non-financial criteria (staff retention, succession, diversity, energy use). Variable pay is capped at 500% of fixed pay. 75% of each bonus is paid in shares, with lock-ups of up to five years. Targets are not published, so the implied hurdle can't be backed out. Including ROIC is better than earnings alone, though revenue growth and EBIT still reward size. The 2024–2028 programme can award up to 442,257 shares (1.9%), bought back or issued (incentivePlanCap). So far it has been funded by buybacks: 90,806 shares were bought for PLN6.4m in February–April 2026 at about PLN70.
peExCash2022–peExCash2025).Decisions that failed or are unproven:
Bench depth beyond the leader: the board grew from three to six in January 2025 (Beksińska, Fryga, Larysz; sgn-fy24-report). The TSS-linked supervisory members bring CSU-family M&A practice; Ioana Corutiu, TSS CFO, has led more than 25 due diligences and 11 integrations (sgn-fy24-report, supervisory-board biographies).
References: none collected. No former employees, customers or counterparties were interviewed, so zero of zero references. The only outside view on record is mBank's 2023–2024 sell rating (target PLN35.80, then 39), and the stock has since more than doubled.
Governing objective: Sygnity has stated none. The controlling shareholder's family manages for return on invested capital, and Sygnity's bonus includes ROIC. Since 2022 the behaviour is consistent with long-term value per share for TSS. For minorities, the open question is whether cash builds up or is returned.
Evidence:
tssServicesPurchased2024 … tssServicesPurchasedH12026). The nature of the charge is not disclosed. In H1 2026 it equalled 18% of net profit, and it is growing faster than profit. It is already expensed, so owner cash is measured after it, but it is a channel for value to reach TSS ahead of minorities. A prospective check tracks it.The three agency costs:
Voting and economic ownership coincide: one share, one vote. TSS controls both.
The main agency cost for an outside holder is the controller's discretion over idle cash, related-party transfers and any future buyout price. How the valuation treats it:
Sources: sgn-rem25, sgn-h126, sgn-fy24-report, sgn-fy25, sgn-tss-call, sgn-gon, sgn-mbank-2024.
PLN millions, calendar years. 2024 and 2025 are statutory years. 2023 is the audited calendar comparative (sgn-fy24 note 44). 2021 and 2022 are derived from the audited fiscal years and the Q1 interims; each year reconciles to the cash balance within PLN0.001m (facts cfoCY2021 … cashEndCY2023). Rates and returns are named audit steps in valuation/calculations.json.
| 2021 | 2022 | 2023 | 2024 | 2025 | Total | |
|---|---|---|---|---|---|---|
| Operating cash flow | 36.4 | 55.1 | 54.8 | 84.1 | 114.7 | 345.2 |
| of which working capital released / (invested) | (7.5) | 18.1 | 0.2 | (0.1) | 14.1 | 24.8 |
| of which incentive add-back (non-cash) | 1.0 | 0.7 | 1.3 | 0.9 | 4.1 | 7.9 |
| of which tax paid | +1.0 refund | (3.0) | (0.6) | (1.8) | (8.6) | (13.0) |
| Capex and capitalized development | (2.8) | (8.2) | (3.8) | (3.1) | (1.8) | (19.6) |
| Lease principal | (7.6) | (7.8) | (5.7) | (4.9) | (4.0) | (30.0) |
| Interest paid | (1.1) | (0.6) | (3.2) | (1.4) | (0.5) | (6.7) |
| Owner cash, after award cost (memo) | 23.9 | 37.7 | 40.9 | 73.9 | 104.4 | 280.9 |
| Acquisitions | — | — | — | (34.3) | (35.7) | (70.1) |
| Debt, bonds and restructuring agreement, net | (15.6) | (18.0) | (12.0) | (12.0) | (12.0) | (69.6) |
| Buybacks (award delivery) | — | — | (0.3) | (0.5) | (4.1) | (4.9) |
| Dividends | — | — | — | — | — | 0 |
| Other investing and financing, FX | 0.0 | 0.0 | 0.7 | 0.2 | (0.1) | 0.8 |
| Net change in cash | 9.3 | 20.4 | 30.6 | 28.1 | 56.6 | 145.1 |
| Cash at year end (42.6 at December 2020) | 51.9 | 72.4 | 102.9 | 131.1 | 187.7 |
The memo line is operating cash flow less the award add-back, capex and development, lease principal and interest. The non-cash add-back is charged there and the cash buybacks appear separately. 2021 operating cash includes the February 2021 e-Taxes settlement (about 14) and 7.5 of working-capital build. 2022 is flattered by 18.1 of working-capital release. Cash tax was minimal until 2025 because of loss carry-forwards.
What the table shows about priorities. Of 345 of operating cash over five years:
The allocator's revealed order was debt first (2021–2025, loans fully repaid in 2025), then deals at about 35 a year. The surplus beyond that was held, and cash then rose further to 225.1 by June 2026.
The window runs from calendar 2020 (revenue 218.7, revenueCY2020) to 2025 (350.3), a change of 131.6 (salesChangeWindow).
| Rate per PLN of revenue change | 2021–2025 | Calculation |
|---|---|---|
| Incremental M&A (acquisitions, no disposals) | 0.53 | 70.1 / 131.6 (maRateWindow) |
| Internally generated intangibles: capitalized development | 0.07 | 9.3 / 131.6 (developmentRateWindow); expensed development is not disclosed |
| Fixed capital, gross capex (before D&A) | 0.08 | 10.3 / 131.6 (fixedRateGrossWindow); an upper bound |
| Working capital | −0.19 (released) | 24.8 of cash released (workingCapitalReleasedRate) |
| Total | ≈0.49 |
Definitions and limits:
Inflection points and who was in charge:
No peer rates were computed.
| 2021 | 2025 | |
|---|---|---|
| EBIT | 34.2 (16.6%) | 89.5 (25.5%) |
| NOPAT at 19% | 27.7 | 72.5 (78.3 before acquisition amortization) |
| Derived owner cash | 23.9 | 104.4 |
| Normalized owner cash (model) | — | 94.6 trailing June 2026; 111.3 for the current portfolio |
acquisitionReinvestmentRate). Including capex and development and netting the working-capital release, net growth capital was 64.9 (totalCapitalDeployedWindow), about 22% of owner cash before capex. The rest went to debt (69.6) or stayed as cash (145.1).incrementalReturnWindow). Lagged one year, capital 2021–2024 was about 41.5 and the return about 108%. These numbers do not measure capital efficiency. Most of the gain is operating leverage and repricing, and it was not bought with capital.| Closing | Deal (seller) | All-in price | Cash acquired | Revenue disclosed | Net profit disclosed | Multiple | Purchase-price intangibles | Later evidence |
|---|---|---|---|---|---|---|---|---|
| Feb 2024 | Edrana Baltic, Lithuanian and Latvian ERP (private seller) | 10.99 (EUR2.54m; 7.46 paid at closing) | 1.58 | 13.6 for 11 months | 2.15 for 11 months | 4.0x annualized net profit on net price | 11.3 | none disclosed after 2024 |
| Mar 2024 | Sagra Technology, Szczecin, retail sales and analytics SaaS (founders) | 40.82 (31.66 at closing; cap 42.3) | 3.20 | 21.9 for 10 months | 3.60 for 10 months | 8.7x | 40.7 | none disclosed |
| Jul 2025 | DocLogix, Vilnius, document management (private) | 7.42 (EUR1.75m) | 0.51 | 5.0 for 6 months | 0.39 for 6 months | 4.35x–9.04x cash proxy (existing DocLogix steps) | 8.1 | — |
| Dec 2025 | Mednow, formerly Comarch HIS, hospital information systems (Comarch) | 24.40 at year end (22.61 after the June 2026 update) | 3.03 | 4.3 for December | 1.04 for December | not measurable from one month; model proxy at 6.61x | 26.2 | — |
| Oct 2026 | g.on experience, Münster, geolocation infrastructure software (TSS, related party) | EUR7.2m initial, about 31.5 | not disclosed | not disclosed | not disclosed | model proxy at 6.61x | — | true-up pending |
Aggregate. About 101.6 of cash over 33 months (February 2024 to October 2026) is about 37 a year, roughly a third of current owner cash. For the two deals with a full year's disclosure, the price was 4.0x–7.1x a cash proxy (deals2024LowerMultiple, deals2024UpperMultiple) and 1.15x annualized revenue. The lower bound credits back purchase-price amortization. The issuer does not report acquired companies' later results, and its organic-growth figure (about 14% in 2025) excludes only 2025 purchases. Edrana's and Sagra's 2025 growth is therefore inside "organic", and the measured deal yield can't be rolled forward. Post-integration margins are not disclosed. The measured multi-year deal yield remains a bound on two first-year results, so the model prices future deals at the CSU-family aggregate (6.61x) and uses Sygnity's own range as a cross-check.
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Deal cash | 0 | 0 | 0 | 34.3 | 35.7 | 35.1 (g.on 31.5 + deferred 3.6) |
recordMean2021to2025); 26.3 over the TSS era 2023–2026 (tssEraMean); 35.1 over the active era 2024–2026 (activeEraMean).The starting point for valuation is consolidated cash after funding the existing business, not an adjusted EBITDA multiple. Development staff and delivery spending remain operating expenses. Sustaining purchases and lease cash are charged. Amortization of acquired customer relationships is not charged a second time as a cash replacement expense.
| Trailing September 2026 bridge (FY2025 + 9M 2026 − 9M 2025, reported 10 Nov) | PLN m |
|---|---|
| Reported operating cash flow | 160.767 |
| Remove working-capital cash contribution | -48.437 |
| Replace paid tax with current tax expense | +2.657 |
| Retain employee-share economic cost | -7.695 |
| Sustaining tangible/intangible cash investment | -1.450 |
| Cash lease principal | -4.677 |
| Financing paid outside operating cash | -0.073 |
| Remove after-tax cash/financial interest | -3.671 |
| Normalized trailing owner cash (current-tax definition) | 97.421 |
| Add back current tax on the excluded working-capital timing | +9.270 |
| September earning power | 106.691 |
The tax adjustment replaces PLN36.354m paid with PLN33.697m of current expense. Current tax itself is inflated by tax on customer advances: the deferred-tax asset on deferred income rose 5.1 and the contract-revenue deferred-tax liability fell 4.2 over the year. The bridge already excludes the 48.4 working-capital inflow those advances created, so it excludes the tax on them too (19% of 48.4 is 9.2). The missing Mednow months (0.534) and the g.on proxy (4.767) give current-portfolio owner cash of 112.0. These are inferred additions, not reported target results; see 07-assumption-register.md. The measured KPO wave (10.2) is removed and the remaining measured base (96.5) is rolled 0.57 years at the 2025 organic growth of about 14% (+7.7), giving the 109.5 anchor run rate. Retained cash earns the measured 1.56% after-tax deposit yield, and deals earn half a year in their purchase year.
September cash of 281.080 is reduced by the g.on initial payment (31.496; closed 2 October, after the balance sheet) and an operating reserve of 73.915 (three months of nine-month cash costs), leaving 175.669 before year-one claims: 9.219 of acquisition and tax payables and 24.447 for the after-tax reversal of the 2026 customer-advance build (contract liabilities 25.6 in September 2025, 85.8 in September 2026). Reserve cash, the joint venture and financial receivables remain assets at face value. Deal cash is a stated yearly budget (08-underwriting-plan.md). Base: 26.3 in year 1, growing 3.4% a year to 35.5 in year 10 (expected budget including quiet-year frequency: active-era pace 35.1 × 0.75). Downside: 0 for three years, then 14.0. Upside: 35.7, 44.2, 44.2, 58.4, 58.4, then 95.0. Idle cash earns the measured after-tax deposit yield (1.56%). The PLN80m facility is not added to cash.
Sources: sgn-fy21, sgn-fy22, sgn-fy23, sgn-fy24, sgn-fy25, sgn-h126, sgn-q121, sgn-q122, sgn-presentation, sgn-gon, sgn-facility, sgn-fx. research/10-capital-efficiency.md holds the engine's forward capital-productivity diagnostics.
Sygnity can compound if two things hold: the repriced incumbent franchise keeps its margin as wages rise, and management buys more software cash at attractive all-in prices instead of letting cash pile up. The causal links are renewals and regulatory change work, cash conversion after staff costs, the actual deal pipeline, and value retained for all common shareholders. TSS affiliation is context, not a substitute for those tests. No supplied Sygnity thesis or target return exists; the company is underwritten independently from filings. The driver plan in 08-underwriting-plan.md was written before returns were calculated.
| At PLN97.00 on 10 November 2026 (exits fixed at 27 Oct 2031 / 2036) | 5-year XIRR | 10-year XIRR |
|---|---|---|
| Downside: revenue −2% then flat, owner-cash margin 24.8% → 23.3% from year 2, three dry deal years then 14.0 a year, 11.45x | −2.7% | 1.7% |
| Base: organic revenue 9.5% / 7% / 5.5%, margin held at 24.8%, expected deal budget 26.3 (+3.4% a year; active-era pace × 0.75 active-year frequency) priced at 1.06x revenue with a 16.2% margin, 15.97x | 10.3% | 10.2% |
| Upside: organic revenue 13% / 11% / 9%, margin 25.3% from year 3, deal budget growing 15%, 15.97x | 14.7% | 14.4% |
| Probability-weighted cash flows (30/50/20; 35/40/25) | 8.08% | 9.27% |
The 10 November roll to the full Q3 report (07-assumption-register.md, 10 November section) replaced the provisional September bridge with reported cash, tax, balances and claims, and measured the KPO wave at 10.2 of owner cash (was a judged 6.06). Run-rate owner cash fell from 113.3 to 109.5; Q3's retained cash raised opening funds, less a 24.4 year-one claim for the reversal of the 2026 customer-advance build. Margins are now the measured starting margin (24.8%, higher because the lower-margin KPO revenue left with its cash) with the same stated downside compression and upside gain. At PLN97 on 10 November, the five-year weighted figure moved from 8.74% to 8.08% (−0.66 points; ten years 9.62% to 9.27%).
The changes were the anchor run-rate starting point (119.8 instead of 111.3), deals earning half a year in the purchase year, a measured 1.56% after-tax return on retained cash, 3.4% growth of acquired businesses, and a 12.2x downside exit. Before the calibration the figures were 1.5/12.4/15.1% and 10.2% weighted over five years. The growth-durability review on the same day removed the KPO hospital wave from starting earnings (119.8 to 115.7) and raised organic growth to 6.51%/11.0%. The five-year figures moved from 1.3/14.1/16.9% (11.5% weighted) to 0.6/14.7/18.8% (12.2% weighted). The bull–bear debate on the same day (12-debate.md) then raised the KPO wave to 6.06 (baseline 113.3), set base deal-capacity growth to 3.4% (a flat deal count), and replaced the 18x and 12.2x exits with a Koller value at a 10.45% market cost of equity (16.0x and 11.5x). Those changes give the table above. Revenue build (3 Nov): the model now projects revenue and margin on yearly paths (08-underwriting-plan.md, Yearly paths). Before it, the debate-judged figures were −0.6/11.9/16.1% and 9.7% weighted (five years). Lumpy deal budget (4 Nov): yearly deal cash from the measured record replaced the smooth cap, moving the five-year weighted figure from 9.65% to 9.39%. The base uses the expected budget including quiet-year frequency. There is no common dividend. Returns come from terminal per-share equity, including retained cash and separately held assets, after claims. The multiple prices normalized after-financing owner cash. The weighted figure is the IRR of probability-weighted dated cash flows, not an average of IRRs.
| Evidence | Multiple | Denominator |
|---|---|---|
| Sygnity year-end market value less cash / net profit: 2022, 2023, 2024, 2025 | 13.3x, 21.6x, 24.0x, 23.8x | peExCash2022–peExCash2025 |
| Today: PLN2,139m less 193.6 of cash after the g.on payment / provisional trailing September net profit 104.6 | 18.6x | equity ex-cash |
| Today: the same / normalized portfolio owner cash 111.3 | 17.5x | model denominator |
| Peak (30 July 2025, PLN118) | about 40x trailing profit | |
| Asseco Poland, trailing P/E (aggregator, 28 Oct 2026; 17.7x in July 2026) | 24.2x | equity, not reconciled |
| Pre-TSS (2019–2021, PLN2–10 during the creditor restructuring) | not comparable | distressed |
Koller check: value = earnings × (1 − g/RONIC)/(r − g). Base terminal growth of 5% is made of about 3% organic growth (near-zero capital) and about 2% from deals at a 15% yield, which needs reinvesting about 13% of earnings. That gives (1 − 0.13)/(r − 0.05).
Debate judgment (3 November 2026). The cost of equity is now estimated, not assumed:
judgedCostOfEquity).The base and upside exit is 0.87/(0.1045 − 0.05) = 16.0x (baseExitMultiple). The 18x it replaced needed r of about 9.8%, below both estimates. The zero-growth value at that r is 9.6x, so the downside is now 11.5x, the midpoint with the 13.3x end-2022 trough (downsideExitMultiple). It was 12.2x at the 9% owner hurdle, and 14x before 3 November. Higher growth in the upside still earns no higher multiple. The Asseco figure in the table is unusable: aggregators show 9–24x depending on the denominator. The bear case below tests 12x.
The price we could sell at after five years if we were not forced sellers, given a specific onerous mechanism:
Result at PLN94: 5-year XIRR −3.0%, 10-year +1.1% (−4.5% and 0.0% before the calibration). Net cash, now earning interest, and retained earnings limit the loss: the business still earns about 96 a year, kept as cash.
Tails this omits:
This is the judged view after the bull–bear debate (12-debate.md), not either advocate's.
History. The market's mispricing ran in our favor from 2022 to 2024. It treated Sygnity as a tender-driven integrator: mBank had a sell rating, forecast 17.6% EBIT for 2025, and the stock ended 2022 at 13x earnings. The unit economics in stage 3 (EBIT per employee from 37k to 104k) and the measured returns in stage 6 showed the repricing the market missed. That gap has closed.
Where the debate left the business. It survived:
What did not survive was the valuation at PLN94:
Returns. On the judged model the base returned 11.9% and the probability-weighted figure 9.7% over five years at PLN94 on 3 November (10.5% over ten). After the 10 November Q3 roll the base is 10.3% and the weighted figure 8.1% at PLN97. That is below a 12% hurdle. The price implies about 3.3% organic cash growth at an 18x exit for a 9% return (no-deal diagnostic, 08-underwriting-plan.md). At 16x the implied growth is higher.
Verdict: fairly priced to slightly expensive for a controlled, low-float company. There is no mispricing in our favor at PLN97 (10 November 2026). The five-year weighted return reaches 12% near PLN81 (was near PLN85 before the Q3 roll).
The deal option on idle cash adds about 2.2 points of base return over no deals (11.9% against 9.6%). It rests on CSU-family purchases at about 15% entry yields. There is no hard catalyst. Possible ones:
freeFloatShares). TSS (72.68%) and Barca (9.01%) do not trade.medianDailyValue3m). Turning over the free float takes about 500 trading days at the median, or 250 at the mean.Neglect is real: low float, a controller, and coverage that was wrong and has lapsed. Part of the discount is justified, though. Minorities can't direct cash, deal terms or a future buyout. That is why the base exit is not set at Asseco's 24x or the stock's own 2023–2025 levels.
| Observation | Where and when | What it would refute |
|---|---|---|
| EBIT margin below 22% in H2 2026 or H1 2027 | FY2026 annual report (about April 2027); H1 2027 report (September 2027) | that the repricing is durable, which supports base cash growth |
| September cash conversion: operating cash after working capital well below the provisional profit bridge (model 106.0; label-implied 100) | Q3 report, 10 November 2026 | the measured base under the 119.8 run rate. Scored 10 Nov: 97.4 on the frozen definition, entirely from current tax on customer advances; 106.7 timing-consistent |
| Organic revenue growth below 8% in Q3 2026 (parent nine-month growth below 10%) | Q3 report, 10 November 2026 | the 14% run-rate roll (+8.2) and the 6.51% base. Scored 10 Nov: parent nine months +14.0%, Q3 alone +9.1%; consolidated organic split not disclosed |
| Nine-month over-time revenue above 110, or Q4 2026 over-time revenue above 40 | Q3 report (10 Nov) and FY2026 report (about March 2027) | the KPO-wave reading; the wave would then return to the base. Nine months 101.7 (above the 80–95 band, not refuted); Q4 open |
| Purchases from TSS Europe above about 17 in 2026, or a new related-party deal | FY2026 related-party note | minority fairness |
| Acquisition cash below 20 in calendar 2027, or deals above 10x cash | FY2027 report | the deal pace and price behind about 2.7 points of base return |
| A second related-party purchase from TSS without disclosed target economics | current reports | minority fairness, pointing to a lower terminal multiple |
| NBP not renewing the ZSK contract beyond December 2027, or a lost Ministry of Family system | current reports in 2027 | franchise durability |
| A special dividend or a regular payout | AGM resolutions, June 2027 | the zero-return cash drag; a favorable surprise |
| Q3 subsidiaries' pretax increase below about 3.5 (KPO wave near the 3.85 tail), or above about 7 (near the bear's 7.4) | Q3 report segment and separate statements, 10 November 2026 | the judged 6.06 KPO wave (debate verdict 3). Scored 10 Nov: 9.65 (range 9.2–10.1); the wave is now the measured residual, 10.2 owner cash |
| Polish 10-year yield below 5.3% or above 7.3% for a quarter | market data | the 10.45% judged cost of equity behind the 16x exit (debate verdict 2) |
| Calendar 2027 deal cash above 45 (capacity growth well above 3.4%) | FY2027 report | the flat-deal-count base (debate verdict 5) |
| A voluntary TSS tender or a delisting resolution | current reports | the minority-exit tail (debate verdict 7) |
The Q3, margin, deal-pace, calendar-2026 and 2027 owner-cash, NBP and debate checks are recorded in valuation/prospective-checks.json. Permanent-loss paths and unverified inputs are updated in 06-risks.md.
Sources: financial facts, named calculations and the method and assumption registers; sgn-fy25, sgn-h126, sgn-9m26-preliminary, sgn-mbank-2024, sgn-price-history, asseco-pe-aggregator, sgn-rem25, sgn-tss-call. No Harvia margin, ROIIC or growth schedule was imported.
Return effects are single-variable diagnostics on the recorded base (5-year base XIRR 12.3% on the revenue build), not probabilities. Figures marked "judged model" predate the revenue build.
The 10 November Q3 report was read and rolled into the model. Next: the g.on price settlement and any IRGA-related change in TSS's 72.68% holding (current reports); Asseco's Q3 report (26 November) as peer context; the FY2026 annual report (date unpublished; FY2025 came on 24 March) for the Q4 over-time cliff, the unwinding of the 85.8 advance balance, the H2 margin, TSS purchases (9M 11.1) and the 2027 deal pace (prospective checks). The parent's Q3 slowdown to +9.1% is the leading growth question.
Sources: sgn-q326, sgn-h126, sgn-9m26-preliminary, sgn-gon, sgn-facility, sgn-calendar, sgn-tss-call, sgn-fy21-report, sgn-fy24-report, sgn-nbp-contract, sgn-rem25, sgn-asseco-h126.
No supplied author forecast/return exists. Exact source calibration is the cash-statement reconciliation and matching accounting perimeter, not an invented historical IRR target. Current scenarios are new dated underwriting. The pre-return plan and self-evaluation remain separate.
| Driver | Observed anchor | Economic mechanism and chosen estimate | What changes it | Model field |
|---|---|---|---|---|
| Earning power | FY2025 and H1 2026 consolidated CFO; sgn-fy25 printed p.8, sgn-h126 p.13; Q3 profit bridge sgn-q325 p.7, sgn-9m26-preliminary p.1 | Remove timing-related working capital, replace paid tax with current expense, charge share awards, capex/leases/financing, remove non-operating interest. PLN94.580m June trailing cash. The 2 November provisional September bridge gives PLN106.026m, and estimated target additions take the portfolio to PLN111.258m (27 October: PLN100.603m). | Actual cash conversion, tax, target results or recurring spending. | baseline.equityCashEarnings; underwritingBridge |
| Organic growth | FY2025 revenue bridge and servicing/implementation tables; sgn-presentation slides 6-8, sgn-h126 p.18 | Installation/servicing demand and regulatory work support cash growth after ongoing costs. Base 6.51% (own 2020–2025 through-cycle rate), downside 0%, upside 11.0%; judgments below recent parent growth, not issuer guidance. Kept by the 3 Nov 2026 debate against the bull's 7.5% and the bear's 5.0%. | Customer retention, tender wins/losses, pricing, wages, maintenance mix and AI competition. | growthRate |
| Employee economics | H1 p.13 CFO addback and pp.27-33 awards/buybacks | Charge economic award cost, keep all issued shares, assume replacements prevent additional dilution. No duplicate buyback expense or free retirement benefit. | Net issuance, award market value, buyback prices and scheme changes. | normalizedTrailingOwnerCash; shares; dilutionRate |
| Operating cash | June cash and cost/contract notes; H1 pp.10, 19 | Hold three months of observed cash operating costs, PLN71.075m, outside deployment. The reserve remains a separately valued asset. | Delivery obligations, advances, payroll needs or restricted cash. | openingCash; retainedAssets |
| Post-period purchase | October g.on release and NBP transaction-date FX | Estimate initial outflow at PLN31.496m. No acquired cash invented. Estimate target cash separately using the disclosed purchase-cash proxy. | Final consideration, actual settlement FX, target cash and operating results. | gonCashPrice; gonOwnerCash |
| Missing Mednow cash | H1 p.23 updated PPA; annual pp.41-42; consolidation from 1 December 2025 | Use updated net capital and the acquisition proxy. The 2 November provisional bridge covers October 2025–September 2026, so only two months are missing: PLN0.527m (27 October June bridge: five months, PLN1.318m). No single December annualization. | Reported stand-alone full-year cash and updated allocation. | mednowMissingCash |
| Purchase valuation | CSU-family 2020–2025 achieved aggregate (see calculations.json aggregate steps); DocLogix annual pp.41-42 as cross-check | 6.61× all-in owner cash (15.1% yield), a family reference class because Sygnity's own record is two to three deals. DocLogix implies 4.35×–9.04× (midpoint 6.70×). | Sygnity's own post-close deal cash, CEE price competition, the implementation mix. | acquisitionMultiple |
| Deployment | FY2025 acquisition cash PLN35.736m (annual p.8); g.on about PLN31.5m (October 2026) | First-year purchases match the observed pace; annual purchases are capped at it, with capacity growth 0%/3.4%/15% by scenario (base: a flat deal count whose cash per deal grows with target earnings, since the 3 Nov 2026 debate; upside: CSU-family reference class). Unplaced cash is retained at face value; no dividend is declared. | Actual pipeline and execution capacity. Cash availability alone is insufficient. | reinvestmentRate; deploymentCapacity; deploymentGrowth |
| Debt and claims | June balance/claims, H1 pp.10 and 28-33; facility amendment | Year-one acquisition/tax claims PLN6.507m; explicit retirement/litigation/bond claims. No extra debt draw; contingent guarantees stress-tested separately. | Settlements, financing use, guarantees called or changes in claims. | cashClaims; retainedClaims |
| Exit value | Business-critical installed base versus project/control risk | Base/upside 16.0x normalized after-financing cash, the Koller value at a 10.45% judged market cost of equity (build-up from the PLN 10-year yield and Damodaran's ERP, averaged with the market-implied rate); downside 11.5x (1/r averaged with the 2022 trough). Cash/assets and claims counted once. Was 18x/12.2x before the 3 Nov 2026 debate. | Durable quality/runway, governance or financing change. | exitMultiple |
| Distributions | June AGM equity statement | No declared common dividend; retain cash. Employee-share purchases do not become shareholder receipts. | Declared payout or changed allocation policy. | payoutRatio; distributionPolicy |
Facts have stable IDs, periods, units and precise locators. Every model input has evidence and an explicit estimate classification where needed. Named calculations preserve the chain from observation to current model. Price changes affect entry cost, not this operating forecast or the terminal multiple. Dated subjective probability weights and revision triggers are recorded separately in research/11-scenario-probabilities.md. The ~15.35% resource control differs from the forecast period-weighted external reinvestment rate; see research/10-capital-efficiency.md.
Sygnity current report 29/2026 (2 November, p.1; Polish original) gives approximate 9M 2026 consolidated revenue PLN336.3m, EBITDA PLN102.2m, pretax profit PLN92.8m and net profit PLN75.9m. It contains no cash flow, balance sheet, tax note or acquisition note. The full report is confirmed for 10 November.
| Input | 27 October (June bridge) | 2 November (provisional) | Basis |
|---|---|---|---|
| Trailing owner-cash base | 94.580 | 106.026 | June bridge plus Q3 2026 − Q3 2025 pretax profit (36.686 − 22.496) at the H1 2026 current-tax rate (21.98%), plus the D&A change, less the capex/lease changes. Q3 2026 costs are estimated as half of H1 |
| Missing Mednow months | 1.318 (5 months) | 0.527 (2 months) | Window now ends September |
| Portfolio owner cash | 100.603 | 111.258 | Plus unchanged g.on proxy 4.704 |
| Base deployment fraction | ~16.12% | ~15.35% | First-year spend held at PLN35.736m; the denominator grew |
Unchanged: opening cash, operating reserve and claims (still June balances less the g.on payment; unreported Q3 cash is not added), exit multiples 18×/14×, growth paths and probability weights.
Mechanism and limits. Replacing a trailing quarter is not annualizing one quarter. Pretax profit already charges employee awards and accrued financing, so neither is deducted again. Unresolved: implementation-revenue timing within Q3, a small change in deposit interest inside pretax profit (H1 2026 cash interest was PLN2.25m), cash tax and working capital. Replace every estimate with the 10 November statements; if September CFO conversion differs, revise the base and record the effect.
Return effect at the same PLN95.90 price and 2 November date (exits fixed): 5-year downside/base/upside 1.06%/12.94%/17.92% versus −0.79%/11.03%/15.96%; weighted-cash-flow XIRR 11.08% versus 9.18%. 10-year weighted 11.54% versus 10.63%.
The serial-acquirer rules adopted for CSU and Lumine (see docs/learning/investor-learning-log.md, 3 November) also apply here. Sygnity is controlled by Topicus, so the CSU-family record is a disclosed reference class, not a borrowed assumption about Polish IT services.
| Input | Before | After | Basis |
|---|---|---|---|
| Purchase multiple | 6.70× (DocLogix midpoint) | 6.61× (family aggregate) | One small deal becomes a cross-check |
| Deal capacity | none: the fraction of resources rose with cash, PLN35.7m → about PLN93m in year five | capped at PLN35.736m, growing 0%/10%/15% | FY2025 annual p.8; g.on shows a flat pace |
| Unplaced cash | retained | retained (stated) | No declared dividend; cash historically accumulated |
| Portfolio owner cash | PLN111.258m | PLN111.333m | Mednow and g.on proxies at the new multiple |
Return effects at PLN95.90, 2 November 2026, exits fixed: 5-year downside/base/upside 1.06%/12.94%/17.92% → 1.07%/11.91%/14.64%; weighted 11.08% → 9.72%. 10-year weighted 11.54% → 9.61%. Probabilities are unchanged. Retaining unplaced cash at zero return is conservative: a future special dividend, as Topicus paid in 2025, would raise the return. The 10 November statements remain the next evidence for both earning power and deployment.
Five years of filings were added (see updates/2026-11-03-pipeline-completion.md). Each finding was checked against the input it bears on:
| Driver | New evidence | Effect on the estimate |
|---|---|---|
Purchase valuation (acquisitionMultiple 6.61x) | Edrana and Sagra 2024: 4.0x–7.1x a cash proxy, depending on amortization push-down (deals2024LowerMultiple, deals2024UpperMultiple) | inside Sygnity's own range; kept |
| Deployment cap (35.7, +0/10/15%) | 34.3, 35.7, about 31.5: flat for three years | kept |
| Organic growth (0/5/8%) | 2021–2025 NOPAT growth was about half margin repricing, a quarter volume and a quarter deals (research/04-capital-allocation.md) | 5% does not extrapolate the repricing; kept, with margin durability as a prospective check |
| Exit (18x / 14x) | own year-end ex-cash P/E 13–24x; today 17.5x on the model denominator; Koller 17–22x at r of 9–10% and g of 5% | 18x kept; 14x downside is generous against an 11x zero-growth value, so the bear case is tested at 12x separately (05-thesis.md) |
| Cash tax | loss carry-forwards exhausted (no tax losses at June 2026; H1 2026 paid 24.3) | confirms charging current tax |
Return effect: none. At PLN94 on 3 November 2026, the 5-year weighted return is 10.17% and the 10-year 9.83%.
The owner's rule: deviating from a referenced investor needs a written, evidence-based reason. The table's forward columns (references/csu-family-cash-pe-2026-11-02.json) imply 109.6 of calendar-2026 and 134.7 of calendar-2027 owner cash; the previous model gave about 119 for 2027.
| Input | Before | After | Named step | Evidence and verdict |
|---|---|---|---|---|
Starting owner cash (baseline.equityCashEarnings) | 111.3 (trailing sum plus proxies) | 119.8 (anchor run rate) | runRateUplift, runRateOwnerCash | The trailing window is centred 0.57 years before the anchor; 2025 organic growth was about 14%. Our trailing restart was a convenience. Adopt-modified. |
| Purchase-year contribution of deals | none | half a year | dealPartYear | Deals close through the year (Feb, Mar, Jul, Dec, Oct). Adopt. |
| Return on retained cash | 0% | 1.56% after tax | retainedCashAfterTaxYield | H1 2026 deposit interest 1.982 on average cash of 206; interest is already excluded from operating cash. Adopt. |
| Acquired-business growth (base, upside) | 0% | 3.4% | acquiredBusinessGrowth | CSU-family 2021-2025 mean organic growth. Adopt. |
| Downside exit | 14x | 12.2x | downsideExitMultiple | 14x sat above the 11.1x zero-growth value; midpoint with the 13.3x 2022 trough. Our own evidence. |
| Base organic growth | 5% | 5% (kept) | baseCashGrowth | The label needs 7.4% only for a 1.6% residual, inside definitional tolerance. The margin has plateaued and the 2022-2025 repricing was one-time. Unresolved; prospective checks. |
| Deal pace | 35.7, +0/10/15% | kept | — | Three flat years of observed pace. Reject the faster-deployment route. |
Return effect at PLN94, 3 November 2026, exits fixed:
| Horizon | Downside | Base | Upside | Weighted |
|---|---|---|---|---|
| 5 years, before → after | 1.48% → 1.27% | 12.37% → 14.14% | 15.11% → 16.92% | 10.17% → 11.52% |
| 10 years, before → after | 2.94% → 3.29% | 11.28% → 12.48% | 13.94% → 15.11% | 9.83% → 10.85% |
Step by step for the five-year weighted rate: run rate +1.41, half-year deals +0.08, cash return +0.16, acquired growth +0.10, downside exit −0.39 points. Probabilities are unchanged (11-scenario-probabilities.md).
The review checked whether the 2025–2026 growth lasts (02-history.md, growth decomposition).
| Input | Before | After | Named step | Evidence and verdict |
|---|---|---|---|---|
| KPO hospital wave in starting earnings | included (119.8) | removed: −3.8 of owner cash, so the baseline is 115.7 | kpoWaveOwnerCash, portfolioExKpo, runRateOwnerCash | Mednow's KPO OPTIMED NXT contracts (22.8 gross, Q1 2026) must be completed by 15 Jul 2026, with spending eligible to 31 Aug 2026 (kpo-d112-schedule). Subsidiaries' over-time revenue rose +35.8 in H1 while their pretax rose only +3.9. Estimated as the subsidiaries' H1 profit increase, less DocLogix and a Mednow base, plus a Q3 tail of 50%; range about 3–8. |
| Run-rate roll | applied to 106.0 | applied to 102.2 (excluding the wave) | organicTrailingBase, runRateUplift | The wave does not recur, so it is not rolled forward. |
| Base organic growth | 5% | 6.51% | baseCashGrowth, organicRatio2020to2025 | Sygnity's own 2020–2025 through-cycle organic revenue CAGR (299.7 / 218.7, fifth root) at a constant margin. The parent's organic growth was 13.4% in 2025 and 16.5–16.8% in each first half since 2024, with maintenance +17–23%. Outside view: CSU-family organic 3.4%. |
| Upside organic growth | 8% | 11.0% | upsideCashGrowth, parentOrganicGrowthRecent | Midpoint of the through-cycle rate and the parent's recent 15.6%. |
Return effect at PLN94, 3 November 2026, exits fixed:
| Horizon | Downside | Base | Upside | Weighted |
|---|---|---|---|---|
| 5 years, before → after | 1.27% → 0.62% | 14.14% → 14.73% | 16.92% → 18.81% | 11.52% → 12.18% |
| 10 years, before → after | 3.29% → 2.95% | 12.48% → 13.24% | 15.11% → 17.03% | 10.85% → 11.83% |
Step by step for the five-year weighted rate: KPO cliff −0.67, base growth +0.70, upside growth +0.63 points. Probabilities are unchanged.
Fact check: the Polish 10-year yield was 6.31% on 3 Nov 2026, not the 6.47% both advocates used.
| Input | Before | After | Named step | Evidence and verdict |
|---|---|---|---|---|
| KPO wave in starting earnings | 3.85 (H1 plus a 50% Q3 tail) | 6.06; baseline 115.66 → 113.28 | kpoWavePretaxQ3Residual, kpoWavePretaxQ3Judged, kpoWavePretaxTrailing | The Q3 subsidiary profit residual (7.0 pretax) contradicts a half-size tail. The residual is an upper estimate, and the known contracts bound the total. Equal weight on both. Split |
| Base and upside exit | 18x | 16.0x | buildUpCostOfEquity, marketImpliedCostOfEquity, judgedCostOfEquity, baseExitMultiple | Build-up r 10.92% (6.31% − 0.72% + 5.33%) and market-implied r 9.98% are averaged to 10.45%, giving Koller (1 − 0.13)/(r − 5%). 18x needed r ≈ 9.8%. Split, leaning bear |
| Downside exit | 12.2x (1/9% hurdle with the 2022 trough) | 11.5x | zeroGrowthMultiple, downsideExitMultiple | The same buyer rate applies to every exit. Consistency |
| Base deal-capacity growth | 10% (family) | 3.4% | binding to acquiredBusinessGrowth | Three flat years; a flat deal count whose cash per deal grows with target earnings. Split |
| Base organic growth | 6.51% | 6.51% (kept) | baseCashGrowth | The bull's 7.5% fade averages 5.7% over ten years, and the bear's EU cap exempts defence and covers a third of revenue. Outside view kept |
| Run-rate roll | 14% | 14% (kept) | runRateUplift | It fills a past window with observed growth; the referenced investor's column needs it. Bull |
| Weights, cash return | 30/50/20, 35/40/25; 1.56% | kept | — | Several attacks survive; the cash yield is measured |
Return effect at PLN94, 3 November 2026, exits fixed:
| Horizon | Downside | Base | Upside | Weighted |
|---|---|---|---|---|
| 5 years, before → after | 0.62% → −0.59% | 14.73% → 11.86% | 18.81% → 16.06% | 12.18% → 9.69% |
| 10 years, before → after | 2.95% → 2.43% | 13.24% → 11.53% | 17.03% → 15.75% | 11.83% → 10.50% |
Step by step for the five-year weighted rate: KPO wave −0.40, deal capacity −0.16, base and upside exit −1.76, downside exit −0.17 points. The weights were reassessed and kept (11-scenario-probabilities.md). Prospective checks were added for the Q3 subsidiary profit, the PLN yield, calendar-2027 deal cash, a June 2027 payout and a TSS tender.
The owner's instruction: an IRR must come from financial projections, with each assumption stated year by year. The model now uses the shared revenue build (revenueBuild, inputs.yearly).
| Input | Before (scalar) | After (yearly path) | Named step or source |
|---|---|---|---|
| Starting revenue | none | 492.2 = (443.5 trailing − 18.5 KPO) × 1.080 + g.on 29.8 + Mednow 3.3 | startingRevenue, kpoWaveRevenue, gonRevenueEstimate |
| Starting margin | implicit | 23.0% = 113.3 / 492.2; KPO wave 18.5 of revenue at 32.8% | startingMargin, kpoWaveMargin |
| Organic growth, base | 6.51% constant | 9.5% (yr 1) · 7% (yrs 2–3) · 5.5% (yrs 4–10) | baseYear1OrganicGrowth; pl-mof-mtfsp; sgn-h126 |
| Organic growth, upside / downside | 11.0% / 0% | 13 / 11 / 9% · −2% then 0% | path reasons |
| Organic margin | implicit, constant | base 23.0%; upside 23.5% from yr 3; downside 21.5% from yr 2 | startingMargin; sgn-fy24 |
| Deal price | 6.61x cash | 1.06x revenue at a 16.2% acquired margin (6.6x cash) | ownDealPriceToSales, acquiredMarginOwnDeals |
| Acquired growth | 3.4% | 0% (yrs 1–2), then 3.4% | sgn-h126; acquiredBusinessGrowth |
Calibration: with constant paths equal to the scalar inputs, the returns matched the debate model exactly (5-year −0.59/11.86/16.06%, 9.69% weighted).
Return effect at PLN94, 3 Nov 2026, exits fixed:
| Horizon | Downside | Base | Upside | Weighted |
|---|---|---|---|---|
| 5 years, before → after | −0.59% → −2.08% | 11.86% → 12.28% | 16.06% → 16.18% | 9.69% → 9.65% |
| 10 years, before → after | 2.43% → 1.63% | 11.53% → 11.40% | 15.75% → 15.11% | 10.50% → 10.07% |
Five-year weighted attribution: organic growth paths +0.06, margin paths −0.12, acquired margin and price +0.02, acquired growth 0.00 points. The ten-year rate falls 0.43 points, mainly from the fading growth (−0.42).
Deal cash is now stated per year (deploymentCapacity.basis: 'yearly-path'). deploymentGrowth is dropped.
| Input | Before | After | Named step or evidence |
|---|---|---|---|
| Base deal cash | 35.7 growing 3.4% (35.7 → 48.3) | expected budget 26.3 growing 3.4% (26.3 → 35.5) | expectedDealBudget = activeEraMean 35.1 × activeYearFrequency 0.75; no dated lumps without evidenced timing |
| Downside deal cash | none (rate 0) | 0 for three years, then 14.0 a year (rate 1) | quietRunYears 3; recordMean2021to2025 14.0 |
| Upside deal cash | 35.7 growing 15% | 35.7, 44.2, 44.2, 58.4, 58.4, then 95.0 | stepped 15% |
| Record measures | — | mean 14.0 (2021–25), 26.3 (TSS era), 35.1 (active era); best year 2.55x the mean; quiet run 3 years | tssEraMean, activeEraMean, recordBestToMean |
A calibration with year-by-year values equal to the smooth cap reproduced the returns exactly.
| PLN94, 3 Nov 2026 | Downside | Base | Upside | Weighted |
|---|---|---|---|---|
| 5 years, before → after | −2.08% → −1.83% | 12.28% → 11.71% | 16.18% → 16.19% | 9.65% → 9.39% |
| 10 years, before → after | 1.63% → 2.12% | 11.40% → 10.90% | 15.11% → 15.13% | 10.07% → 9.94% |
The base first used dated quiet years (years 3 and 8: 11.86%, 9.47%). It was corrected the same day to the expected budget, because the timing of quiet years is not evidenced.
The nine-month report (sgn-q326, Polish original, published 10 November) replaces the 2 November provisional bridge.
| Input | Before | After | Named step or source |
|---|---|---|---|
| Trailing window | June 2026 (FY2025 + H1 2026 − H1 2025) plus a preliminary-profit Q3 increment | reported September 2026 (FY2025 + 9M 2026 − 9M 2025) | the …Ttm steps; sgn-q326 p.11 |
| Normalized owner cash, current-tax definition | 94.58 (June) + 11.45 provisional Q3 = 106.03 | 97.42 reported | normalizedTrailingOwnerCash |
| Current tax on excluded working-capital timing | not separated | +9.27 (deferred-tax asset on deferred income +5.07; contract-revenue liability −4.20, Sep 2025 to Sep 2026) | advanceTaxTiming; sgn-q326 p.20, sgn-q325 note 12.2 |
| September earning power | 106.03 provisional | 106.69 | preliminaryUpdatedOwnerCash |
| Q3 KPO wave | judged equal-weight mean, 4.31 pretax (trailing wave 6.06 owner cash) | measured residual, 9.46 pretax (10.23 owner cash) | kpoWavePretaxTrailing now uses kpoWavePretaxQ3Residual; parent Q3 reported (+4.53 ex estimated dividends, against an assumed +6.96) |
| KPO wave revenue | 18.5 (Q1 contracts 22.757 gross) | 65.5 (H1 contracts 80.544 gross, same nine hospitals) | kpoWaveRevenue; contradiction between the Q1 and Q3 reports recorded |
| Anchor run-rate owner cash | 113.28 | 109.49 | runRateOwnerCash |
| Starting revenue / margin | 492.2 / 23.0% | 441.4 / 24.8% | startingRevenue, startingMargin |
| Downside margin from year 2 / upside from year 3 | fixed 21.5% / 23.5% | starting margin −1.5 / +0.5 points (23.3% / 25.3%) | downsideLaterMargin, upsideLaterMargin |
| Opening cash | June 225.1 − g.on 31.5 − reserve 71.1 = 122.5 | September 281.1 − g.on 31.5 − reserve 73.9 = 175.7 | investableCash; g.on closed 2 Oct (note 35) |
| Year-one claims | 6.51 (June payables) | 9.22 payables + 24.45 advance-build reversal = 33.67 | knownCashClaims, advanceReversalClaim |
| Retained claims and assets | June values | September: retirement 1.563, litigation 0.538, bond 0.100, JV 0.983, receivables 0.451 | sgn-q326 pp.9, 27–28 |
Why each change:
parentQ3DividendShare). Bounds of 0 and 1 move the five-year weighted figure by +0.06 and −0.07 points.Return effect at PLN97, 10 November 2026, exits fixed (old model and new model at the same quote and date):
| Horizon | Downside | Base | Upside | Weighted |
|---|---|---|---|---|
| 5 years, before → after | −2.45% → −2.68% | 11.05% → 10.30% | 15.52% → 14.69% | 8.74% → 8.08% |
| 10 years, before → after | 1.80% → 1.66% | 10.57% → 10.20% | 14.80% → 14.39% | 9.62% → 9.27% |
One-at-a-time reversals of the five-year weighted figure: measured KPO wave −0.59, advance-reversal claim −0.17 and the tax-timing add-back +1.22 points (against the strict definition). The KPO revenue estimate is neutral once margins are relative (+0.01). Weights are unchanged (11-scenario-probabilities.md, 10 November).
This plan records the business logic and intended assumptions before calculating shareholder IRRs. The work is new underwriting from issuer evidence, not a Harvia-style source-return reproduction.
Added 3 November 2026, after the original 27 October plan below and after returns had been calculated. It tests the existing scenario inputs and changes none of them. Money in PLN millions; all figures are judgments built from the cited facts.
| Opportunity | Starting point | Customer need and why Sygnity wins | Reachable scale in 5 years | Investment and cash cost | Timing and limits | Evidence against |
|---|---|---|---|---|---|---|
| Price on installed systems (indexation and repricing at renewal) | servicing 144.2 in 2025; NBP up to about 27 a year; six Ministry of Family 48-month contracts from 2024 | continuity of statutory and central-bank systems; incumbent code and staff | inflation-linked: roughly 3–5% a year on the recurring base, about 25–40 of revenue | none beyond staff already in costs | at each renewal (NBP end-2027; ministries 2028) | public buyers retender on price; the 2022–2025 repricing may already have taken the slack |
| Volume: regulatory and functional change requests on own systems | implementation 189.0, much of it change work on installed systems | legal deadlines (energy market, labour-market reform, NBP needs) leave customers no time to switch | follows legislation; we assume 0–3% a year net of fading programmes | delivery staff at about 0.19 per FTE a year; roughly 6 people per 2.9 of revenue | lumpy; Solidarity Shield and CSIRE work is fading | utilities growth of +34% since FY2022 is partly temporary |
| Share: new tenders and new public systems | public-sector projects 83 in 2024 | domain references; price decides at tender | not underwritten as growth; replaces lost or expiring work | bid costs, guarantees (13.1 outstanding), fixed-price risk | 2026–2029 EU and KPO cycle | e-Taxes failure; Asseco's scale |
| Acquired niches: organic growth | about 51 of revenue (Sagra, Edrana, DocLogix, Mednow, g.on) | vertical software with maintenance | at 5–8% a year, +15–25 of revenue | small; working capital in SaaS is low | already in the base | no post-acquisition results disclosed |
| Acquisitions | 34.3 (2024), 35.7 (2025), about 31.5 so far in 2026 | sellers (founders, Comarch, TSS) get a permanent CSU-family owner | at about 35–52 a year (base cap growing 10%), about 220 deployed over 5 years at 6.61x, adding about 33 of owner cash | cash only; no debt or equity | each deal contributes from the year after purchase; integration capacity of one or two deals a year | Sygnity's own record is two measurable deals; related-party supply (g.on) |
| KPO hospital wave (Mednow OPTIMED NXT) | nine KPO hospital contracts of 22.8 gross (Q1 2026); subsidiary over-time revenue +35.8 in H1 2026 | hospitals had to spend recovery funds by the deadline | none after 2026: projects completed by 15 Jul 2026, spending eligible to 31 Aug 2026 | delivery staff and licences | ends Q3 2026; afterwards maintenance on the installed hospitals | removed from starting earnings (about 3.8 of owner cash); a Q4 2026 over-time level near Q2's would refute the wave reading |
| Idle cash | 225.1 at June 2026; about 75 a year beyond deal spend | — | 600 or more by year five if not used | none | policy choice for TSS and the AGM | no dividend since at least 2021 |
Scale check five years out (base): existing-business owner cash grows 5% to about 142. At constant conversion that is roughly 570 of existing-business revenue against 443.5 trailing September 2026 (provisional), plus about 150 of revenue from new deals at the 2024 deals' 1.15x price-to-sales, with their own staff. At today's 0.41 revenue per FTE plus 3% a year indexation, the existing business would need about 1,200 staff instead of roughly 860 now, about 7% a year of net hiring. That is feasible in Polish IT but adds to wage pressure. Management targets are not published, so there is no guidance to test against. The base sits below the company's recent revenue growth (+19.5% in 2025; +38% in the first nine months of 2026, provisional), which included repricing and acquisitions.
Each case is a coherent business outcome. Growth, margin, required capital, deal capacity, financing, dilution and the exit denominator move together and are recorded in valuation/model.json inputNotes.
| Downside | Base | Upside | |
|---|---|---|---|
| Organic revenue growth (yearly path) | year 1 −2%, then 0% | year 1 9.5%, years 2–3 7%, years 4–10 5.5% (10-year mean 6.2%) | year 1 13%, years 2–3 11%, years 4–10 9% |
| Organic owner-cash margin (yearly path) | 23.0% in year 1, then 21.5% (back to the 2024 level as wages outrun indexation and NBP and the ministries reprice) | 23.0% held (group EBIT 25.5% → 25.2%; repricing done at group level) | 23.0% in years 1–2, then 23.5% (mix shifts to the higher-margin parent) |
| Required capital | none (negative working capital) | none beyond expensed staff | none |
| Deal capacity and price | yearly budget: 0 for three years (the worst dry spell in the record), then 14.0 (2021–2025 mean) | yearly budget: 26.3 in year 1, growing 3.4% a year to 35.5 in year 10 (expected budget including quiet-year frequency: active-era pace 35.1 × 0.75); no lump or quiet year is placed in a specific year because no deal timing is evidenced; 1.06x price per zloty of revenue at a 16.2% margin; half a year in the purchase year; acquired revenue flat in years 1–2, then +3.4% | yearly budget: 35.7, 44.2, 44.2, 58.4, 58.4, then 95.0 (15% capacity growth); same price and margin |
| Return on new capital | — | 15.1% entry cash yield | 15.1% |
| Financing and dilution | no debt; awards bought back; zero net dilution | same | same |
| Unplaced cash | retained, earning the measured 1.56% after-tax deposit yield, counted at face value | same | same |
| Starting revenue and margin | revenue 441.4 (reported trailing 443.5, less the 65.5 KPO wave, rolled 0.57 years at 14%, plus g.on 29.8 and Mednow 3.3 estimates); owner cash 109.5; margin 24.8% (10 Nov 2026; was 492.2 / 113.3 / 23.0%) | same | same |
| Exit denominator and multiple | 11.45x normalized after-financing owner cash (judged: 1/r at 10.45% averaged with the 13.3x 2022 trough) | 15.97x (Koller at r = 10.45%) | 15.97x: higher growth does not earn a higher multiple |
Temporary under-use versus permanent impairment: idle cash is temporary under-use, valued at face and not destroyed. A permanent impairment would be a lost core system or a structural margin reset; those sit in the bear case (05-thesis.md) and the risks register, not in the downside path. Deals are funded from cash before their earnings are recognized. The capacity cap reflects one or two integrations a year, not the cash available.
Outside view (growth-durability review, 3 November). Five-year organic owner-cash growth is 0%, 6.5% and 11.0%. Including deals, base owner cash grows from 115.7 to about 197 in year five, about 11% a year. 6.5% organic is in line with Sygnity's own 2020–2025 through-cycle record. It is twice the CSU-family organic mean (3.4%), which the parent's maintenance growth supports. The upside's 11% for a decade is above what most mature IT-services companies sustain and depends on the parent's recurring growth persisting; it carries a 20–25% weight. The KPO wave is a funding deadline, not demand that recurs, so it is removed rather than extrapolated.
Diagnostic at PLN94 on 3 November, base with no deals: 2% growth at 18x gives 7.9%, 3% gives 8.8% and 4% gives 9.7%. The market price implies about 3.3% organic cash growth at an 18x exit for a 9% return.
Author calibration (3 November): the CSU-family cash P/E table implies 134.7 of calendar-2027 owner cash. The base now gives 132.6 (−1.6%), against 118.7 before.
Regulated banking, public administration and utility customers buy implementations and ongoing servicing of business-critical software. Servicing is a repeat-business anchor, but projects and public procurement remain substantial. Sygnity is not a pure subscription vendor. Product development, implementation staff, subcontractors and incentive compensation remain economic costs.
Use the shared after-financing cash-equity adapter. Normalize trailing consolidated operating cash flow for working-capital and tax-payment timing; deduct sustaining cash investment, cash leases, financing paid outside operating cash and the employee-share addback. Remove income on cash/financial assets valued separately. Do not deduct acquisition amortization again or charge an arbitrary industrial organic ROIIC on top of software costs already expensed.
Use FY2025 + H1 2026 - H1 2025. Keep current taxes, investment cash, employee awards and deposit income separately identifiable. Preserve the actual published CFO bridge before normalization. Employee-share buybacks fund awards; charging the economic award cost means no second future award-buyback charge or free share-count accretion.
Start from June cash. Subtract the initial EUR7.2m g.on price using the transaction-date NBP EUR/PLN reference rate as an estimated cash payment. Retain an operating reserve equal to one quarter of observed cash operating costs because contract delivery and advance receipts create funding obligations. Reserve cash remains an asset at face value, outside the acquisition budget. No interest on it is capitalized into operating earnings.
Treat the June deferred acquisition payable as a year-one cash claim. Carry reported pension and litigation provisions, the small bond balance and the JV/other financial assets explicitly. Cash leases are charged in earnings; lease principal is not deducted again as a separate terminal debt. No new credit draw is assumed. The PLN80m facility includes a PLN30m guarantee sub-limit and a PLN50m overdraft; a facility limit is neither cash nor a shareholder asset.
The October g.on release discloses a price but not stand-alone owner cash. Mednow is in only seven months of the trailing window. Estimate missing mature cash using a disclosed acquisition-cash proxy, not a one-month December profit annualization. Mark these additions as estimates, not reported earning power or guaranteed synergies. Hold the estimates constant across scenarios until better target evidence is available.
DocLogix provides a small, imperfect empirical anchor: a six-month post-purchase net profit contribution, the purchase price, acquired cash, transaction costs and the purchase-price intangible asset balance. Annualize the six-month contribution only as a rough proxy, with explicit seasonality limitations. The lower cash-multiple estimate reverses after-tax acquisition amortization using an estimated eight-year useful life within the disclosed 5-11 year range. The upper estimate gives no cash credit for that amortization. Use the midpoint of these alternative cash definitions for a base purchase multiple. This is not an observed portfolio hurdle or a proof that future deals will earn it.
Set the base deployment fraction so the first modeled year's purchase budget matches FY2025 actual acquisition cash spending, given the current investable cash plus estimated first-year owner cash, after known cash claims. It is a calibration to observed deployment pace, not to an IRR. Keep that fraction fixed thereafter and inspect the resulting annual deal sizes. Faster deployment requires more actual deal capacity, not just available financing. New purchases occur at year-end and earn cash the following year; no early mature earnings is recognized.
| Case | Existing-business cash growth | New purchases | Exit valuation | Economic interpretation |
|---|---|---|---|---|
| Downside | 0% | None | 14x after-financing owner cash | Project demand and the acquisition platform stall; cash accumulates, with no unsupported extra permanent margin haircut. |
| Base | 5% | Fraction calibrated to FY2025 cash deployment; midpoint purchase-cash proxy | 18x | Maintenance, regulatory work and implementations grow more slowly than recent reported results; acquisition discipline and deployment stay near observed capacity. |
| Upside | 8% | Twice the base initial deployment fraction, same purchase-cash multiple | 18x | Stronger product/servicing demand and a broader deal pipeline; no extra terminal re-rating or lower purchase price. |
Growth, deployment and terminal valuation are explicit estimates. Recent FY2025 revenue excluding newly acquired companies grew roughly 14%, but that is not a perpetual cash-growth forecast. A 5% base requires continuing product investment already charged to cash earnings. The 18x multiple is a valuation judgment reflecting installed mission-critical software, balanced against project exposure, public-sector procurement and controlling-shareholder risk. It is not copied from Harvia, Lumine or CSU, and not solved from a target return. The 14x downside reflects weaker durability and minority-marketability concerns. Probabilities are not assigned.
Check the published cash balance identity, consolidated versus parent-only accounts, all ownership claims and cash-tax timing. Change one financial observation and confirm the calculation trail changes. Change only the live quote and confirm the operating forecast does not change. Test zero deployment, slower cash growth, an acquisition-price increase, a delay in acquisition contribution, a lower exit multiple, and a separate guarantee-loss stress. No scenario probability or author endorsement is implied by these tests.
Sources: issuer FY2025 consolidated statements; H1 2026 consolidated statements; April 2026 investor presentation; October acquisition release; September facility notice; October reporting-calendar notice; NBP transaction-date FX; competitor Asseco H1 2026 release. Customer contract notices corroborate demand mechanisms, not forecast revenue recognition.
Owner cash is now revenue × margin. Each assumption is stated per year range with its reason and sources in valuation/model.json (cases.*.inputs.yearly); the starting point is in named steps startingRevenue and startingMargin.
Starting point. Trailing October 2025 to September 2026 revenue was 443.5 (FY2025 audited plus the reported 9M 2026, less 9M 2025; the 10 November report confirmed the preliminary figure). The KPO hospital wave is removed as revenue and margin, not only as cash: 65.5 net of VAT (the nine Mednow hospital contracts, 80.5 gross per the Q3 report; the Q1 report had said 22.8 for the same hospitals), carrying 10.2 of owner cash, a 15.6% margin (kpoWaveRevenue, kpoWaveMargin). The rest is rolled 0.57 years at 14% to the anchor. Estimates are then added for g.on (29.8) and Mednow's two pre-consolidation months (3.3), both at Sygnity's own 1.06x price-to-sales. That gives starting revenue of 441.4 against owner cash of 109.5, a 24.8% margin. Before the 10 November roll: 18.5 KPO revenue at 6.06 owner cash, 492.2 revenue, 113.3 owner cash, 23.0%.
| Path | Base (years: value) | Why |
|---|---|---|
| Organic growth | 1: 9.5% · 2–3: 7% · 4–10: 5.5% | Year 1 weights the parent (69% of ex-KPO revenue, organic 13.4–16.8% since 2024, maintenance +17–23%, ministry renewals) at 13% against subsidiaries at 2% (point-in-time revenue flat in H1 2026). Years 2–3 fade under the EU deficit procedure's net-expenditure path (4.0% in 2027, 3.5% in 2028; defence exempt) and the NBP renewal due in December 2027. Years 4–10 are long-run growth just below the 6.51% through-cycle rate. The 10-year mean is 6.2%. |
| Organic margin | 1–10: starting margin, 24.8% since 10 Nov (was 23.0%) | Group EBIT margin was flat at 25.5% (2025) and 25.2% (H1 2026). The parent is still rising (core 26.1% → 32.6%), but low-margin acquired units offset it. Wage growth (+5.3% per FTE) is passed into renewals. |
| Price per zloty of acquired revenue | 1–10: 1.06x | Own deals net of cash: Edrana 0.63x, Sagra 1.43x, DocLogix 0.69x. At the acquired margin this is 6.6x cash, the CSU-family aggregate. |
| Acquired margin | 1–10: 16.2% | Edrana 15.8% and Sagra 16.4% first-year net margins; DocLogix 7.9%; subsidiaries about 14% after tax in H1 2026, against the parent's 32.6% core margin. |
| Deal budget | 1: 26.3, growing 3.4% a year to 35.5 in year 10 | Expected budget including quiet-year frequency. Deal cash was 0, 0, 0, 34.3 and 35.7 (2021–25), plus 35.1 so far in 2026. The active-era pace (35.1) is multiplied by the TSS-era active-year frequency (0.75) and grown at the 3.4% verdict. No deal has been announced, signed or financed, so no lump is put in a specific year. g.on was paid before the anchor. |
| Acquired growth | 1–2: 0% · 3–10: 3.4% | Subsidiaries' point-in-time revenue was flat in H1 2026; after that the CSU-family organic mean. |
Base rows, years 1–5 (revenue / organic / acquired / margin / owner cash): 555.8 / 538.9 / 16.9 / 22.8% / 128.7; 627.9 / 576.6 / 51.3 / 22.5% / 144.3; 704.9 / 617.0 / 87.9 / 22.2% / 161.2; 778.0 / 650.9 / 127.1 / 21.9% / 177.2; 855.5 / 686.7 / 168.7 / 21.7% / 194.3. The blended margin falls because acquired revenue earns 16.2%.
Calibration: constant paths equal to the previous scalar inputs (the margin at 23.0%, acquired margin at 23.0%, price-to-sales at 6.61 × 23.0%) reproduced the debate model exactly: five-year −0.59/11.86/16.06%, 9.69% weighted.
The economic plan was saved before the first return calculation. The analysis uses Sygnity's own consolidated financials, delivery/servicing mix and incentive/funding structure.
The FY2025 and H1 cash statements reconcile from opening to closing cash, including investing, financing and translation. The model uses consolidated cash, rather than the parent-only cash statement containing subsidiary dividends. The original Polish table confirms the Mednow purchase allocation is in PLN thousand despite English prose saying EUR. Statutory revenue tables take precedence over presentation sub-bars that do not sum to their headline.
The latest Mednow allocation is used, with the original provisional value left in the source record. Acquisition-year timing is respected: DocLogix is effectively fully consolidated in the current trailing window, Mednow has seven months, and g.on is absent. Known-target missing cash is estimated separately rather than treating a closing-month profit as a full-year run-rate.
The owner-cash bridge retains employee incentive cost, actual capital purchases, leases and tax. Changing the compensation observation reduces cash through the calculation trail without reducing the share count for free. Operating reserves, legacy taxes/payables, financial assets, claims and contingent guarantees have separate treatment. Facility limits are not assumed cash.
All results below use PLN90.90, 27 October 2026, and a 27 October 2031 exit. They are single-variable diagnostics around the recorded base. They are not probabilities, confidence limits or source-author forecasts.
| Counterfactual | Estimated five-year XIRR | What it tests |
|---|---|---|
| Recorded base | 12.18% | Current-portfolio cash grows 5%; purchases start near observed cash spending. |
| No future acquisitions | 8.29% | Cash alone does not guarantee an opportunity set. |
| No organic cash growth | 8.05% | The base depends on existing products and delivery economics too. |
| New purchases cost 50% more per cash euro | 10.24% | Available money is not the same as attractive purchase returns. |
| New purchases contribute one additional year later | 10.98% | No free mature cash before the investment contributes. |
| Exit multiple 14x rather than 18x | 7.56% | Terminal judgment is material. |
| Full PLN13.078m guarantee cash call in year one | 12.00% | Contingent cash risk, without pretending it measures consequential business damage. |
| Remove both estimated current-target additions | 10.94% | Unreported target earning power is not silently treated as known. |
Changing only the share price preserves forecast rows. Missing compensation evidence, source references and model inputs are validated. The company uses the existing shared cash-equity and XIRR engines; no company-specific executable valuation code was added.
The purchase-cash proxy rests on a six-month DocLogix result and an estimated amortization life. Tax timing, current-target profitability, future project cash needs and deployment capacity can all differ. The forecast gives actual first-/last-year purchase budgets so that sourcing requirements are visible: base approximately PLN35.7m to PLN88.9m, upside PLN72.4m to PLN156.4m. A finite history does not prove that expansion can continue.
The downside is a coherent stalled-growth/deployment case, not a bound on loss. A permanent software impairment, dilution, unfair related-party deal or collapsing project margin can be worse and needs separate evidence. Base and upside retain the same purchase and terminal multiples, preventing an unsupported extra re-rating from manufacturing the favorable result.
Issuer releases, the financial statements, business/product pages and a competitor release were read. Some PGE/customer pages timed out, and no comprehensive current customer-budget survey or g.on stand-alone filing review is claimed. Q3 results on 10 November are the next confirmed event to replace current proxies.
Money is in PLN millions. These calculations use the researched scenarios and the shared forecast ledger. They are forward diagnostics, not independently measured historical ROIIC or realized acquisition IRRs. Local sensitivities may differ.
| Period | Scenario | Capital return / proxy | Period-weighted reinvestment | New growth capital | Matching earnings |
|---|---|---|---|---|---|
| 5 years | downside | 15.3% | 5.2% | 28.031 | 542.912 |
| 5 years | base | 15.3% | 18.4% | 140.724 | 765.707 |
| 5 years | upside | 15.3% | 27.2% | 240.936 | 884.568 |
| 10 years | downside | 15.3% | 8.4% | 98.109 | 1162.796 |
| 10 years | base | 15.3% | 15.8% | 307.055 | 1940.120 |
| 10 years | upside | 15.3% | 27.8% | 715.936 | 2578.506 |
Updated 10 Nov 2026 after the Q3 roll (anchor run rate 109.5 after the measured 10.2 KPO wave). Deal budgets are unchanged, so new growth capital is unchanged; matching earnings are about 3% lower.
Deal cash is a stated yearly budget (4 Nov 2026). The base uses the expected budget (26.3 growing 3.4%), which prices quiet years in without dating them; the downside is dry for three years, then deploys 14.0 a year.
Revenue build (3 Nov 2026): the deal return proxy is now the acquired margin (16.2%) divided by price-to-sales (1.06x), 15.3%, and base deal capacity grows 3.4% a year (debate judgment).
Return definition: Acquisition ROIIC · mature cash proxy. Numerator 33.023 / denominator 218.172. Earnings basis: After-financing common-owner cash, after ongoing operating investment. The forecast runs from 2026-10-27 to 2031-10-27; a ten-year selection uses its own summed ledger. No historical lagged ROIIC is claimed; the CSU-family 2020–2025 aggregate acquisition yield that sets the purchase multiple is in valuation/calculations.json (aggregate steps).
Average period reinvestment is total new growth investment / total matching earnings, not the arithmetic mean of annual rates. The base available-cash deployment control is 14.9%; annual purchases are also capped by the observed deal capacity, growing at the scenario's capacity growth, so the 27.1% five-year weighted rate is lower than an uncapped forecast. Matching earnings now include interest on retained cash. Old acquisition claims, dividends, debt repayment and financial stakes do not acquire a second increment of operating profit.
Five-year base funding: cash generated before new investment 787.510, less distributions 0.000, less old claims 6.507, plus opening cash drawn / (cash built) -640.280, plus net borrowing / (deleveraging) 0.000. This funds growth capital 140.724 and separately funded financial stakes 0.000. Reconciliation error is below 0.000001.
New-cohort earnings at exit / period investment: 15.9% (cohorts are flat for two years, then grow 3.4% a year).
Limits:
Definitions and original methodology links are in docs/method/cash-flow-and-reinvestment.md; source locators are in this company’s registry. Probabilities are separate judgments recorded in research/11-scenario-probabilities.md.
Assessment date: 2026-10-27. These are initial subjective judgments, with low confidence. Financial sources support the mechanisms, not measured numerical odds. The original authors did not provide or endorse these weights.
| Horizon | Downside | Base | Upside |
|---|---|---|---|
| 5 years | 30% | 50% | 20% |
| 10 years | 35% | 40% | 25% |
5-year reasoning: Installed software and servicing contracts support cash durability, but project concentration, control/related-party issues and sparse target cash data limit confidence in both organic growth and acquisition deployment.
10-year reasoning: Longer customer/product transitions and a larger deployment opportunity set widen outcomes. Lower central weight reflects weaker visibility into a decade of purchases and minority-holder economics.
Downside: Tender timing, weaker project conversion or governance concerns can stall growth and acquisitions. Cash retention limits this representative loss path, but severe contract or capital-allocation damage can be worse.
Base: Existing servicing/development demand supports 5% after-spending cash growth. Base purchases begin near the reported annual deployment amount rather than assuming every available zloty finds a suitable target.
Upside: Stronger product growth and a more productive acquisition pipeline support the 8% growth/twice-deployment case. The limited transaction sample and related-party safeguards limit its current weight.
Review triggers:
Each path represents a broad outcome region, not the probability of hitting an exact share price or IRR. Paths are a coarse approximation of a continuous joint distribution; the displayed downside and upside are not bounds. Joint driver dependencies must be considered, rather than multiplying marginal driver guesses. Scenario weights sum to 100% within this approximation. Severe outcomes remain possible outside the modeled paths.
Price movement alone does not change these weights. A changed causal premise, acquisition capacity, financial report or scenario definition does. Local assumption sensitivities suspend the researched weights until the full distribution is reassessed. No weighted-average IRR is presented as an expected shareholder return.
Sources: sgn-fy25, sgn-h126, sgn-gon, sgn-asseco-h126. Method: Damodaran, chapter 33, printed pp.894-897. See valuation/model.json for machine-readable weights and docs/method/cash-flow-and-reinvestment.md for the capital definitions.
Weights unchanged. Stronger preliminary Q3 profit raises the provisional earning-power base in every path, but it doesn't settle cash conversion, implementation lumpiness, target economics or controlling-shareholder risk. A four-number release can't support a finer numerical odds revision. Reassess after the 10 November statements.
Scenario definitions changed: deals are priced at the CSU-family aggregate and capped at the observed pace, with capacity growth of 0%/10%/15%. The upside no longer deploys a doubled resource fraction without limit. Weights are reassessed and kept, because the change constrains every path rather than shifting their relative likelihood.
Weights unchanged at 30/50/20 (5 years) and 35/40/25 (10 years). The five-year filings support the mechanisms behind each path:
They don't justify a finer numerical change. The bear mechanism in 05-thesis.md (margin back to about 21%, no deals, 12x; −4.5% over 5 years) lies below the downside path. It is a tail inside the downside region's 30% weight, not a fourth weighted path. Price changes alone do not move the weights.
Scenario definitions changed in every path:
These are measurement and timing corrections common to all paths. They don't shift the relative likelihood of the business outcomes, so the weights were reassessed and kept at 30/50/20 (5 years) and 35/40/25 (10 years). The Q3 report on 10 November is the next trigger.
Weights kept at 30/50/20 and 35/40/25. The review split H1 2026 growth into the parent's durable organic growth, which supports a higher base and upside, and a KPO deadline wave inside Mednow, which is removed from every path. Neither finding changes which business outcome is more likely relative to the others; both change the level of every path. The upside's 11% organic growth sits above outside-view base rates, which argues against raising its weight. The 10 November Q3 report is the next trigger.
Weights kept at 30/50/20 (5 years) and 35/40/25 (10 years). The judgment (12-debate.md) changed the scenario definitions:
These change the level of the paths more than their relative likelihood, so the weights were reassessed rather than carried over.
Next trigger: the 10 November Q3 report.
Weights kept at 30/50/20 and 35/40/25. The paths now state revenue and margin per year. The downside gained an explicit margin decline (the bear's mechanism), and the base fades its growth. These restate the same three business outcomes in more detail; they do not change their relative likelihood.
Weights kept. The yearly deal budget states the record's lumpiness inside each path: quiet years in the base, and a three-year dry spell in the downside. It does not change the relative likelihood of the three outcomes.
Weights kept at 30/50/20 and 35/40/25, reviewed against the nine-month report. The roll changed the level of every path (measured KPO wave, reported cash and claims), not their relative likelihood. Evidence that could move the weights, in both directions:
No numerical odds come from the report. These remain subjective judgments. Next trigger: the FY2026 annual report.
Run under prompts/debate.md after the valuation stage. The bull and bear advocates wrote their cases separately, then cross-examined each other. A judge who did not build the base case decided each contested point. The advocates' working papers (sygnity-bull.md, sygnity-bear.md and their rebuttals) are local scratch files and are not tracked. This page summarizes them. All returns come from the shared engine at PLN94 on 3 November 2026, with exits fixed at 27 Oct 2031 and 2036. Before the debate the model gave 0.62/14.73/18.81% at five years (12.18% weighted) and 2.95/13.24/17.03% at ten (11.83% weighted).
The bull steelmanned the bear first: the 2022–2025 margin step was a one-off, wages rise about 8% a year, two-thirds of H1 2026 growth was acquired, and a controller hoards cash. His opening case then had five claims:
parentRevenue*, parentMaintenance*; sgn-h126 p.44, FY2025 JSF p.28). NBP raised the ZSK ceiling by 25 gross (sgn-nbp-contract). There were 37 public awards worth 195 gross (mimira-awards). The mechanism is legislation-forced change requests on systems the customer can't switch.peExCash2023–2025), and Asseco trades at 24.2x (asseco-pe-aggregator).Combined, these gave a 5-year weighted return of 16.9%. The bull conceded up front the flat deal pace, the 6.61x deal price, a held (not expanding) margin, no take-private premium and removal of the KPO wave.
The bear steelmanned the bull's installed-base franchise and said permanent loss is hard to construct with 194 of net cash. His case was that several optimistic choices stack:
pbtQ3Change; sgn-9m26-preliminary). Projects had to be complete by 15 July (kpo-d112-schedule). Taking out the parent's H1 pace and a Mednow base leaves about 6 of Q3 pretax, against the 1.6 assumed. Wave: 7.4, not 3.85.runRateUplift): −4.4 of owner cash.Combined (1+2+3+4+5a), these gave 6.67% base and 6.08% weighted over five years.
Cross-examination narrowed both cases.
Fact check. Both advocates used a stale shared fact. The Polish 10-year yield was 6.31% on 3 November 2026, not 6.47% (te-pl10y). The remaining checks:
| # | Claim | Bull | Bear | Evidence | Verdict | Reason |
|---|---|---|---|---|---|---|
| 1 | Base organic growth | 7.5% (fade from 16.8%) | 5.0% (EDP ceiling) | Parent organic growth is measured. The fade path is asserted. The engine applies one rate to both horizons. The EU cap is an aggregate ceiling that exempts defence | Split: keep 6.51% | The bull's own path averages 7.4% over five years and 5.7% over ten; 6.51% sits between. The bear's cap covers a third of revenue and didn't stop public revenue growing 28% under the same procedure. Balanced evidence keeps the outside view, which is Sygnity's own through-cycle rate |
| 2 | Exit multiple | 18x | 14.5–16x (r ≈ 11.8%) | Build-up r = 6.31 − 0.72 + 5.33 = 10.92% (Koller 14.7x). The market paid 17.5x on 3 Nov, which implies r = 9.98%. Own history 13.3–24x, but 2023–25 came with 20–35% growth. Asseco unusable | Split, leaning bear: 16.0x (baseExitMultiple) | 18x needs r ≈ 9.8%, below both estimates. The two estimates of the buyer's rate are weighted equally, giving r = 10.45%. That r also applies to the downside: 1/r = 9.6x, so the downside exit is 11.5x (was 12.2x) |
| 3 | KPO wave in starting earnings | 5.6 | 7.4 | The Q3 subsidiary residual after the parent's H1 pace, the new Mednow PPA charge and the Mednow base is 7.0 pretax, against a 1.6 tail. The deadline makes Q3 a peak. The known contracts (22.8 gross, about 18.5 net) bound the total. The parent's Q3 pace is assumed | Split: 6.06 (kpoWavePretaxQ3Judged) | The evidence contradicts a half-size tail (bear). The residual is an upper estimate, since it also absorbs subsidiary organic growth and any parent acceleration, and 9.1 pretax would be a 49% margin on the known contracts. The two estimates are weighted equally until the 10 Nov notes |
| 5 | Base deployment growth | 5% | 0% | Three flat years: 34.3, 35.7, about 31.5. The family rate is 10%. More platforms is an asserted mechanism | Split, mechanism-based: 3.4% (acquiredBusinessGrowth) | The record supports a flat deal count, not 10% growth. A zero nominal rate for ten years would shrink the real pace. With a constant count and multiple, cash per deal grows with target earnings (the family's 3.4% organic rate). Upside keeps 15% |
| 6 | EU deficit cap and defence exemption | the cap doesn't bind Sygnity | a 3.5% ceiling | Verified as above | Bull on the mechanism; no input | The ceiling applies to total net expenditure and exempts defence. It still limits civil budget growth to about 4% through 2028, which argues against going above the through-cycle rate. Recorded as a reason for verdict 1 |
| 7 | Tender floor versus refusal and squeeze-out | refusal blocks it | −6.6% path | Arts. 73, 79, 82, 91. TSS already holds more than 50%, so any tender is voluntary. Delisting needs 9/10 of votes cast with Barca present | Unresolved; no input | Not a forced outcome while Barca holds 9.01%. It is still a coercive tail: a tender at the floor after a drawdown, with a delisting threat. It stays inside the downside weight, which is therefore not lowered |
| 8 | Weights | 25/50/25; 30/45/25 | recorded (40/45/15 withdrawn) | Several attacks survive (see Conviction) | Keep 30/50/20; 35/40/25 | The surviving attacks argue against raising the upside weight. Parent evidence argues against raising the downside weight |
| 9 | Cash return | 2.8% | measured 1.56% | H1 2026 deposits yielded 1.92% pre-tax | Bear | Measured, not hypothetical. +0.14 points if changed |
| 10 | Deal price 9.04x; g.on value; payout | — | — | — | 6.61x kept; g.on unresolved; payout withdrawn | 9.04x is a definitional bound, not a price. g.on lacks data rather than having contrary data. A payout is a prospective check at the June 2027 AGM |
Model effect (PLN94, 3 Nov 2026, exits fixed; five-year weighted change in brackets):
| Step | 5-year d/b/u, weighted | 10-year d/b/u, weighted |
|---|---|---|
| Before | 0.62 / 14.73 / 18.81, 12.18 | 2.95 / 13.24 / 17.03, 11.83 |
| KPO wave 3.85 → 6.06 (baseline 115.7 → 113.3) | 0.24 / 14.33 / 18.38, 11.78 (−0.40) | 2.75 / 13.06 / 16.83, 11.64 |
| Base deployment growth 10% → 3.4% | 0.24 / 14.03 / 18.38, 11.62 (−0.16) | 2.75 / 12.50 / 16.83, 11.40 |
| Base and upside exit 18x → 16.0x | 0.24 / 11.86 / 16.06, 9.86 (−1.76) | 2.75 / 11.53 / 15.75, 10.56 |
| Downside exit 12.2x → 11.5x (after) | −0.59 / 11.86 / 16.06, 9.69 (−0.17) | 2.43 / 11.53 / 15.75, 10.50 |
Single-claim sensitivities around the judged model (5-year weighted 9.69%):
Even the bull's weights would leave it below 12%. Named steps are in valuation/calculations.json, inputs and reasons in valuation/model.json inputNotes, and the record in updates/2026-11-03-debate-judgment.md.
Attacks that survived rebuttal:
Conviction: low to moderate. The business case survives: an installed-base franchise, measured organic growth, net cash and no plausible permanent loss in the representative paths. The investment case does not survive at PLN94. The judged 5-year weighted return is 9.7% (10.5% at ten years), below a 12% hurdle. The exit-multiple attack was rebutted only by pointing to today's price, which can't be the evidence that the price is cheap.
What would change it: the 10 November Q3 report. Parent nine-month organic growth of at least 15%, with subsidiaries' Q3 profit showing the KPO wave was near the 3.85 tail, would restore about 0.4 points and support the bull on growth. Even then the cost-of-equity verdict leaves the weighted return near 10%. On the same model, the five-year weighted return reaches 12% at about PLN85 and 13.3% at PLN80, which is around the art.79 floor area. A durable fall in Polish long yields towards 5% would lower the build-up cost of equity. Either would make the case investable; neither would raise conviction in the business itself.
The judged verdicts are kept, and the model now projects revenue and margin year by year (08-underwriting-plan.md, Yearly paths). A calibration with constant paths reproduced the judged figures exactly: 5-year −0.59/11.86/16.06%, 9.69% weighted.
The revenue build then exposed three things the scalar engine hid:
New returns at PLN94: 5-year −2.08 / 12.28 / 16.18%, 9.65% weighted; 10-year 1.63 / 11.40 / 15.11%, 10.07% weighted. The conviction rating above is unchanged.
The engine now takes a stated yearly deal budget. Measured record: 0, 0, 0, 34.3 and 35.7 (2021–25), and 35.1 so far in 2026. The 2021–25 mean is 14.0, and the best year is 2.55 times the mean. The TSS-era mean is 26.3, the active-era mean 35.1, and the longest quiet run three years.
The budget refines the 3.4% capacity-growth verdict rather than replacing it. The base uses the expected budget including quiet-year frequency: the active-era pace (35.1) × the TSS-era active-year frequency (0.75) = 26.3, grown at the 3.4% verdict. No lump or quiet year is placed in a specific year, because no deal timing is evidenced (rule in prompts/stages/08-forecast.md). An earlier draft put quiet years in years 3 and 8 and gave 11.86% / 9.47%; that draft was replaced. The downside repeats the three-year dry spell, then deploys the record mean.
A calibration with the smooth path reproduced the earlier figures exactly. New returns at PLN94: 5-year −1.83 / 11.71 / 16.19%, 9.39% weighted; 10-year 2.12 / 10.90 / 15.13%, 9.94% weighted.
Primary filings, investor communications, and industry evidence.
SSF_Sygnity_2025-12-31_pl_EN.pdf: printed pp.4-8 statements; pp.31-33 revenues/tax; pp.41-42 acquisitions; p.46 JV. PDF pages are printed pages +1.
Published Mar 24, 2026 · Reviewed Oct 27, 2026Consolidated section only: pp.9-13 statements; p.18 revenue; p.20 interest/tax; p.23 updated Mednow allocation; pp.26-33 shares/claims/incentives. Header says PLN thousand; some English table labels incorrectly say EUR.
Published Sep 3, 2026 · Reviewed Oct 27, 2026Original-language cross-check of units and consolidated statements. English prose contains erroneous EUR labels in the Mednow PPA; the underlying tables are PLN thousand.
Published Sep 3, 2026 · Reviewed Oct 27, 2026Slides 6-10 visually inspected: organic/acquired revenue, sectors, maintenance versus implementation and cash. Slide 8 implementation sub-bars do not add to the headline; use statutory revenue tables for numerical inputs.
Published Apr 22, 2026 · Reviewed Oct 27, 2026One-page release: wholly owned Tessara Blue buys 100% of g.on from TSS Europe; initial EUR7.2m subject to post-close settlement. Target earning power and acquired cash are not disclosed.
Published Oct 2, 2026 · Reviewed Oct 27, 2026PLN80m total: PLN50m overdraft plus PLN30m guarantees, subject to conditions. No new drawing is reported here.
Published Sep 7, 2026 · Reviewed Oct 27, 2026Q3 January-September 2026 publication moved from 12 November to 10 November 2026.
Published Oct 13, 2026 · Reviewed Oct 27, 2026Polish page checked 10 November 2026: current reports through 29/2026 and the nine-month 2026 periodic report (posted 10 November). October g.on and reporting-date notices read.
Reviewed Nov 10, 2026Business-critical software, implementation and maintenance; TSS control since 2022; 2018 restructuring; management and controlling-shareholder background.
Reviewed Oct 27, 2026Maximum remuneration increases by PLN25m gross to about PLN135m gross for the January 2024-December 2027 contract. A gross contract cap is not annual net revenue or immediately earned cash.
Published Jun 12, 2026 · Reviewed Oct 27, 2026Poland segment growth, recurring servicing, public/healthcare digitalisation and competitive capacity. Context for sector demand; does not establish Sygnity market share.
Published Aug 27, 2026 · Reviewed Oct 27, 2026Table 192/A/NBP/2026, EUR mid 4.3745 PLN. Transaction-date translation proxy, not the issuer actual booked/payment rate.
Published Oct 2, 2026 · Reviewed Oct 27, 2026Yahoo chart endpoint metadata matched SGN.WA, PLN and WSE. Price/timestamp retained in local quote cache; not an earnings input or a terminal-multiple reset.
Reviewed Oct 27, 2026pp.8, 18-23: cash-flow identity, intangible capital and lagged multi-year ROIIC. Calculation guidance, not company-specific forecast assumptions.
Published Oct 6, 2022 · Reviewed Oct 27, 2026Cash-in/cash-out and economic compensation; multi-year retained capital, incremental earnings, limitations. A signed worked framework, not a source for the company numerical inputs.
Published Aug 26, 2023 · Reviewed Oct 27, 2026Printed pages 894-897: coherent scenarios, estimating probabilities and scenario-weighted cash flows. No company probability is supplied.
Reviewed Not reviewedp.1, original Polish issuer release, visually inspected. Revenue336.3, EBITDA102.2, pretax profit 92.8, net profit 75.9, PLN m, approximate. No cash flow/balance sheet. Full report confirmed for 10 November2026.
Published Nov 2, 2026 · Reviewed Nov 2, 2026Consolidated pp.7,9,13; prior nine-month revenue/profit and D&A/capex/lease comparatives. Cash-flow p.13 visually inspected.
Published Nov 12, 2025 · Reviewed Nov 2, 2026Current report 29/2026 posted 2 November2026 at 15:37 local. English index lags this preliminary report; check original-language and regulatory current releases.
Reviewed Nov 2, 2026PDF p.4 organic growth; p.10 Topicus Coop preference units; p.12 FCFA2S reconciliation (2021 and 2020); p.15 cash used in acquisitions (2021 and 2020).
Reviewed Nov 3, 2026PDF p.6 organic growth; p.18 cash used in acquisitions.
Reviewed Nov 3, 2026PDF p.5 organic growth; p.18 cash used in acquisitions.
Reviewed Nov 3, 2026PDF p.5 organic growth and quarterly organic table; p.13 FCFA2S reconciliation (2025 and 2024); p.18 cash used in acquisitions (2025 and 2024).
Reviewed Nov 3, 2026PDF p.3 WideOrbit purchase price, special shares and parent cash funding; p.14 preferred shares issued for cash proceeds.
Reviewed Nov 3, 2026PDF pp. 13 FCFA2S; 15 ownership cash; 17 liquidity; 27 balance sheet; 32 cash flows; 35–40 acquisitions; 42–44 investments; 46–50 debt; 52 financing and shares; 54 claims; 55–59 NCI and subsequent events. Printed page numbers are one lower.
Published Aug 11, 2026 · Reviewed Oct 27, 2026Consolidated Financial Statement FY21.pdf: PDF p.5 income statement, p.8 cash flows, p.33 other operating revenue, p.48 share capital, p.50 shareholders, p.57 employment.
Reviewed Nov 3, 2026Activity report for the Sygnity Group and Sygnity S.A..pdf: PDF p.23 sales by sector and projects; p.24 Fast Enterprises e-Taxes settlement.
Reviewed Nov 3, 2026CONSOLIDATED FINANCIAL STATEMENT.pdf: PDF p.5 income statement, p.8 cash flows, p.9 shareholders, p.34 costs by type, p.57 employment.
Reviewed Nov 3, 2026REPORT ON THE ACTIVITIES ... 2022-09-30_EN.pdf: PDF p.25 sales by sector and projects.
Reviewed Nov 3, 2026Consolidated Financial Statements.pdf: PDF p.8 cash flows; pp.58-59 note 43 comparable 1 Oct 2021-31 Dec 2022 income statement and cash flows; p.56 employment.
Published Mar 31, 2024 · Reviewed Nov 3, 2026Report on the Sygnity Group and Sygnity S.A. Activities.pdf: PDF p.25 sales by sector and projects.
Published Mar 31, 2024 · Reviewed Nov 3, 2026Consolidated Financial Statements.pdf: PDF p.5 income statement, p.9 cash flows, p.35 costs by type, pp.44-45 Edrana Baltic and Sagra acquisitions and goodwill, pp.62-63 note 44 calendar-2023 comparable statements.
Published Apr 30, 2025 · Reviewed Nov 3, 2026Report on the Operations of the Sygnity Group and Sygnity S.A..pdf: PDF p.25 sales by sector; pp.32-34 contracts (Ministry of Family, Poczta Polska, Solidarity Shield, CSIRE); p.39 M&A strategy; p.55 competition risk.
Published Apr 30, 2025 · Reviewed Nov 3, 2026PDF p.8 cash flows; p.11 selected data (revenue, EBIT).
Reviewed Nov 3, 2026PDF p.5 selected data; p.8 cash flows.
Reviewed Nov 3, 2026PDF p.9 table 3.1.1 board pay; p.14 table 4.1 bonus criteria (net profit, EBIT, ROIC, revenue growth); p.17 tables 4.2.3-4.2.4; p.24 2024-2028 incentive programme.
Published May 6, 2026 · Reviewed Nov 3, 2026PDF pp.1-6: call conditions, TSS strategic intent and delisting reservation, PLN12.00 price and VWAP comparison.
Published Apr 6, 2022 · Reviewed Nov 3, 2026p.1 rating, forecasts 2024-2026 and multiples; risk section on tender pricing and no dividend. Used only as a dated record of the outside view, not as evidence of economics.
Published Oct 10, 2024 · Reviewed Nov 3, 2026Daily closes and volumes retrieved 3 Nov 2026; unofficial, delayed.
Reviewed Nov 3, 2026P/E 24.2x as of 28 Oct 2026 (17.7x on 19 Jul 2026). Aggregator figure, not reconciled to filings; peer context only.
Reviewed Nov 3, 2026PDF p.17 revenue streams and timing; pp.33-34 significant agreements incl. Mednow KPO hospital contracts.
Reviewed Nov 3, 2026SSF i JSF SGN H1FY25 EN.pdf p.16 revenue; SZD_GK SGN 20250630 EN.pdf p.21 sales by sector.
Reviewed Nov 3, 2026PDF p.17 revenue streams and timing.
Reviewed Nov 3, 2026Q3 2026 consolidated report: 10 November 2026.
Reviewed Nov 3, 2026Slides 2-3: hospital completion 15 Jul 2026, eligibility 31 Aug 2026.
Published Mar 11, 2026 · Reviewed Nov 3, 202614.84% treasury shares at PLN85, closed 1 Oct 2025; earlier 9.99% from Cyfrowy Polsat. Combined 24.84% per secondary analysis.
Reviewed Nov 3, 2026Art.73(1) mandatory tender above 50%; art.79(1)-(3b) minimum price: 3- and 6-month VWAP, highest price in 12 months, fair value by an audit firm if illiquid; art.82 squeeze-out at 95%; art.83 sell-out at 95%; art.91(3),(5) delisting by 9/10 of votes cast with half the capital present, after a tender for all remaining shares. Text in force on 3 Nov 2026.
Reviewed Nov 3, 202637 awarded lots, PLN195.07m, 1 Jan 2025-27 Jul 2026; mostly MRPiPS maintenance and development.
Reviewed Nov 3, 2026Full text behind a bot challenge; claims recorded from search-result extracts only: Q2 revenue 111.5, over-time revenue 49.5 (2.28x the best earlier quarter), point-in-time revenue -19% y/y, hypothesis of KPO-funded implementations, nine Mednow KPO hospital contracts (22.8).
Reviewed Nov 3, 2026Price about PLN28m; Comarch e-health revenue about PLN50m in 2024 (-40% on 2023); Asseco healthcare PLN217m; PLN3bn of KPO funds for hospital digitization in Sept 2025.
Published Oct 3, 2025 · Reviewed Nov 3, 2026Episode description only (transcript behind login): some investors see these as the best way to own the CSU model; the bear view is thinner deal flow and AI risk.
Published Apr 5, 2026 · Reviewed Nov 3, 2026Headline: yield 6.31% on 3 Nov 2026, 0.98 points higher than a year ago. Both debate advocates had used the 15 Sep 2026 reading of 6.47%.
Published Nov 3, 2026 · Reviewed Nov 3, 2026Poland row: Moody's A2, rating-based default spread 0.72%, country risk premium 1.10%, total equity risk premium 5.33%; mature-market premium 4.23%.
Published Jan 5, 2026 · Reviewed Nov 3, 2026Local-currency riskfree rate = local-currency government bond yield less the country default spread; the country risk premium is then added through the equity risk premium, so it is counted once.
Published Dec 1, 2008 · Reviewed Nov 3, 2026Recommended net-expenditure growth 6.3% (2025), 4.4% (2026), 4.0% (2027), 3.5% (2028); Council recommendation ST 5037/25 Annex I. The procedure remains open (Council decision 26 Jul 2024, EUR-Lex 2024/2133).
Published Jan 21, 2025 · Reviewed Nov 3, 2026Adopted 8 Jul 2025: Poland may deviate from the net-expenditure path to the extent of higher defence spending. Poland's own 2026 forecast exceeds the path within that flexibility.
Published Jul 8, 2025 · Reviewed Nov 3, 2026Polish original, 48 pages, PLN thousand. Printed pp.8-11 consolidated statements; p.17 revenue/timing/costs; pp.18-20 finance income and tax; pp.25-34 cash, shares, provisions, payables, related parties, contingencies, post-period g.on closing; pp.36-42 commentary and holdings; pp.45-48 parent statements. No English version was posted at review time (EN path returned 404).
Published Nov 10, 2026 · Reviewed Nov 10, 2026